Biotin × Falsely low TSH measurement bias

Measurement-bias brief

Measurement question: After oral biotin exposure, what direction and magnitude of measurement bias were observed in specific serum TSH assays in healthy adults, compared with the same people before exposure/after washout or comparator platforms using specimens from the same time point? Distinguish findings by platform, reagent version, dose, dosing duration and time from the last dose to blood draw.
Outside this scope: Thyroid function/treatment effects, diagnostic accuracy/actual misdiagnosis/patient harm rates, all analytes/reagents, a universal stopping interval, and extensions to safe human doses/special populations are separate questions.
Meaning of verification status: The preceding verification statuses describe the verification scope of each narrow record condition; they are not badges of efficacy, absence of interference or individual safety.
Safety record: The original safety status is Warning. This reflects the possibility that falsely low TSH could lead to interpretation errors; the direct observations are assay-specific bias and reference-limit crossing. The incidence of actual patient harm is not an established result.
Document-quality record: The retained document-quality record is B, separate from the magnitude of the measurement effect or an individual safety grade.

Required evidence, verification status and materials actually read
Item	AVerification status	BReading scope	CReview item	DCurrent findings	EWhy unverified	FRequired materials and conditions	GFurther research
1	Met	Full text not readStored summary read	N01 · Measurement-only displayDoes this table address a measurement question and prevent the application of efficacy grades and scores?Required	The original data have measurement_only=true, question_type=measurement. Efficacy grade·score·axes are not_applicable, and efficacy badges, aggregate ratings and a universal stopping interval are prohibited. The original grade ?·score null are not used as a new efficacy assessment.	This documentation condition links the original measurement classification and display prohibitions unchanged. It does not mean certification of clinical efficacy or absence of interference.	Measurement-only classification, fields marking efficacy as not applicable, and a display contract prohibiting efficacy badges/aggregate ratings/a universal stopping interval	Cross-check the display paths for measurements, reagent performance, document quality and patient outcomes separately to prevent conflated labeling.
2	Met	Full text not readStored summary read	N02 · Separate question and familyWhich exposure, specimen, comparison and measurement outcome are brought together in one table?Required	The single claim concerns falsely low readings in specific serum TSH assays after oral biotin. The actual comparisons are within the same people before exposure and after washout, or between platforms using specimens from the same time point; they do not concern biotin's thyroid treatment effect or actual misdiagnosis rates. S01 S04 S05 S08	The original claim and the boundaries of the measurement family were verified. Results from some assays were not extended to all TSH assays or clinical diseases.	The original claim and a fixed question specified by healthy adults, oral exposure, serum TSH, platform/reagent, dose and blood sampling time	Construct a matrix of platform, reagent, exposure and time point, and cross-check measurement bias separately from physiological changes/clinical outcomes.
3	Met	Full text not readStored summary read	N03 · Analyte and unitsWhich TSH measure in which specimen does the observed outcome represent?Required	The selected outcome is the serum TSH assay value. Li's TSH is in mIU/L and the Roche document's criteria are in µIU/mL; these are distinguished from blood biotin in pg/mL and document values in ng/mL. The original units were not converted and combined. S01 S03 S08	The condition distinguishing the retained original units and analytes was verified. Physiological thyroid status was not determined.	Serum TSH analyte, units, time-point/contrast definitions, and separate blood biotin units	Cross-check analytes, units and measures against each original table/document without generating new converted values or clinical status classifications.
4	Unverified	Full text not readStored summary read	N04 · Exposure product and chemical formAre the actual form, batch and total exposure to the biotin supplement known?Required	Oral biotin supplement exposure is retained in the record, but the manufacturing source, exact chemical form, tablet/capsule, composition, batch, purity and total dietary exposure remain unverified. S01 S04 S05	The currently retained information does not identify product details or total actual exposure. The nominal dose was not used to fill these gaps.	Exact chemical form, formulation, batch, purity and dosing records for the study product, and total dietary exposure data	Link study product specifications and actual intake records to measurements by platform/time point to compare differences between products.
5	Partly verified	Full text not readStored summary read	N05 · Oral dose and timelineWere dosing duration and the interval from the last dose to blood sampling distinguished?Required	Li used 10 mg/day for 7 days, with sampling approximately 2 hours after the last dose on day 7, and after 7 days off on day 14. Zhang used the same 10 participants at 5/10 mg/day for 7 days each; Ylli used 10 mg/day for 8 days, with measurements on day 1/day 8 before dosing and at 2 hours and 5 hours. S01 S04 S05	The reported timelines were linked, but not all records of individual actual intake/timing and total dietary exposure were verified.	Nominal oral dose, dosing start/end, actual last dose and blood sampling times for each trial	Cross-check dose, dosing duration, last dose and blood sampling time against the original records as separate axes.
6	Partly verified	Full text not readStored summary read	N06 · Population and representativenessTo which populations can the measurements in healthy adults be applied?Required	The detailed direct evidence from Li and Zhang concerns healthy adults. Ylli has an abstract-level record of 13 adults, while the detailed analysis population remains unverified. These data do not establish the magnitude/duration in patients, people with renal impairment, pregnant people, children or high-dose treatment groups. S01 S04 S05	The scope of the reported population is available, but detailed recruitment/baseline characteristics and general applicability are currently unverified.	Recruitment/selection, baseline thyroid/renal function, age/sex composition and special-population data for each trial	Cross-check population composition and baseline status against exposure/measurement conditions, and assess applicability to other populations using direct data from those populations.
7	Met	Full text not readStored summary read	N07 · Li participants and specimensWhat denominators do Li's 6 people and 18 time-point specimens represent?Required	Li compared 6 healthy adults before exposure, on day 7 and on day 14. The 18 serum time-point specimens were not treated as 18 participants or 18 independent samples. S01	The retained distinction between participant and repeated-specimen denominators was verified. This did not newly establish every detailed analysis denominator.	Li's participant count, time-point specimen count, and measurement/analysis and exclusion flow by platform	Cross-check the correspondence among participants, specimens, platforms and time points against the original flow/tables to verify the unit of analysis.
8	Partly verified	Full text not readStored summary read	N08 · Zhang's same participantsDo Zhang's two doses represent trials with different groups of 10 people each?Required	In Zhang, the same 10 healthy adults used 5 mg/day and 10 mg/day for 7 days each. The exact numbers of analyzed specimens by platform and time point remain unverified. S04	The boundary of the same 10 people is clear, but detailed analyzed-specimen denominators remain unresolved.	Identity of the same participants, exposure order and duration, and analysis flow by dose/platform/time point	Cross-check exposure order, washout intervals and period effects within the same people to verify the dependence of repeated measurements.
9	Partly verified	Full text not readStored summary read	N09 · Ylli enrollment and analysisDo Ylli's 13 people constitute the analysis denominator for every TSH value?Required	Ylli is recorded as having enrolled 13 adults. Extraction is limited to the abstract and figure captions; detailed TSH analysis denominators and quantitative full-text tables remain unverified. S05	The enrollment count and level of material were retained, and the actual analysis n was not arbitrarily fixed at 13.	Ylli's enrollment/completion/TSH analysis denominators, and specimen flow for each original quantitative table and figure	Map enrollment counts and analysis populations/time points to the original tables to verify the scope of missingness and exclusions.
10	Partly verified	Full text not readStored summary read	N10 · Design and exposure orderWhat comparisons does the actual design provide, and what does it fail to control?Required	Li is a nonrandomized comparison within the same people before exposure, after exposure and after washout, and between platforms using the same specimens. Zhang uses a fixed sequence, and Ylli uses prospective within-person exposure comparisons. These were not treated as treatment effects between randomized placebo groups. S01 S04 S05	The actual design descriptions are verified, but detailed controls for order, concurrent changes and blinding remain unverified.	Actual exposure order, concurrent changes, control of background factors, and measurement/reading conditions	Distinguish comparisons across time points within the same people from comparisons of concurrent specimens to assess the effects of order, time and background changes.
11	Partly verified	Full text not readStored summary read	N11 · Comparison referenceWhat comparison references do pre-exposure/post-washout measurements and other platforms provide?Required	The actual comparisons involve the same people before exposure and after washout, and platforms using specimens from the same time point. Comparisons with biotin-independent methods are relevant to verifying measurement interference, but are not diagnostic tests that establish a patient's thyroid status. S01 S02 S04	The content of the comparisons is linked; independent reference methods/true values and diagnostic accuracy have not been verified in these materials.	Definitions of time contrasts, and analytical principles and traceability/reference-method information for comparisons using the same specimens	Cross-check paired time contrasts and assay differences in specimens from the same time point separately, and distinguish them from determining a clinical true value.
12	Partly verified	Full text not readStored summary read	N12 · Analytical principles and instrumentsWere the principles and instrument identities of the TSH assays distinguished?Required	Distinguish Roche cobas e602, Ortho VITROS 5600, Siemens Dimension Vista 1500, Abbott ARCHITECT 2000 and Zhang's Beckman UniCel DxI 800. Also retain Vista's biotin dependence and the biotin independence of Zhang's Beckman/Abbott TSH assays with their respective results. S01 S02 S04	Differences in retained instrument identities and principles are available, but historical lots and actual reagent installations in individual laboratories have not been fully verified.	Instruments, reagents, principles, specimen procedures and interference tolerance thresholds for each analyte	Cross-check not only instrument names but also the TSH reagents' capture/detection methods against the results at the exposure tested.
13	Unverified	Full text not readStored summary read	N13 · Historical reagents and current installationsAre historical tests and current reagents with the same instrument name being treated as identical?Required	Historical reagent lots and interference tolerance thresholds remain unverified. Roche's 2024-10 V2.0 document provides a known version boundary, but does not verify reagent identity at the time of the trials or currently across all laboratories. S01 S04 S08	The required identity of lots/installations cannot be established from instrument names alone.	Reagent lots and method versions at the time of the trial, revision histories and actual laboratory installation records	Map instruments, reagents, versions and installation dates to verify identity/differences between historical trials and current documents.
14	Met	Full text not readStored summary read	N14 · Li formal contrastWhich repeated-measures contrast does Li's formal estimate represent?Required	Li's formal estimate is day 7 − mean(day 0, day 14). It is a repeated-measures contrast within the same participants, not a simple change from baseline or an effect between two randomized groups. The reported 95% CI is the interval from the original model. S01	The formal contrast definition and attribution of the CI were verified. No new estimation or variance calculation was performed.	Formal repeated-measures contrast formula and model, and original estimates/CI/P for each platform	Cross-check the original contrast formula and time-point means to distinguish formal model results from historical simple arithmetic values.
15	Met	Full text not readStored summary read	N15 · Li Roche valuesWere Li Roche's formal bias and historical simple difference distinguished?Required	Li Roche cobas e602 TSH was 1.80→1.21→2.06 mIU/L, with a formal contrast of −0.72 mIU/L, 95% CI −1.13~−0.32, P = 0.006. −0.59 mIU/L is the historical simple before/after difference between the displayed means; it was not newly calculated. S01	The retained original Roche values and the distinction between the two contrasts were verified. They were not extended to current reagents or patient treatment effects.	Li Roche TSH time-point means, formal contrast, original CI/P and display of historical arithmetic	Map platform/time-point means and the formal contrast definition to the original table to verify the roles of the different values.
16	Met	Full text not readStored summary read	N16 · Li Ortho valuesWhat is the scope of Li's VITROS values and observations relative to the lower reference limit?Required	Ortho VITROS 5600 had means of 1.64→0.10→1.89 mIU/L, a formal contrast of −1.67 mIU/L, 95% CI −2.08~−1.26, P < 0.001. After exposure, all 6 participants were below 0.15 mIU/L, and the assay's lower reference limit was 0.47 mIU/L. S01 S02	The retained platform values and lower limit were linked accurately. They were not converted into actual hyperthyroidism or a misdiagnosis rate.	VITROS time-point means, formal contrast/CI/P and the method's lower reference limit	Distinguish the original formal contrast from individual reference-limit crossings and attribute them to the platform's measurement results.
17	Met	Full text not readStored summary read	N17 · Boundaries for reference limits and misdiagnosis ratesWas crossing the lower reference limit expressed as sensitivity, specificity or an actual misdiagnosis rate?Required	The VITROS observation that all 6 participants were below the lower limit after exposure is a measurement under these conditions. It was not converted into a population misdiagnosis rate, incidence of actual hyperthyroidism or diagnostic sensitivity/specificity. S01 S02 S09	This condition preserves the source's stated boundary for extending measurements to clinical outcomes. It does not mean there is no patient harm.	The method's reference limit, individual measurements and actual clinical assessments/follow-up outcome data	Compare assay reference-limit crossings, independent clinical status and post-test actions separately; do not estimate patient rates without that connection.
18	Met	Full text not readStored summary read	N18 · Li Vista contrary observationWas the nonsignificant result for biotin-dependent Vista also preserved?Required	In the same Li specimens, Siemens Dimension Vista 1500 had −0.11 mIU/L, 95% CI −0.49~0.26, P = 0.56. Vista TSH is biotin-dependent, but there was no significant difference at this exposure. This was not interpreted as bias of 0 or equivalence. S01 S02	The difference between the original negative finding/interval and the principle was preserved as recorded.	Vista's original assay principle, paired estimate, CI/P and the exposure conditions	Relate the negative observation and the range of bias still compatible with it to the original interval/exposure conditions, distinguishing them from other platforms.
19	Met	Full text not readStored summary read	N19 · Li Abbott comparator methodWas Li's nonsignificant Abbott estimate kept within the scope of the comparator method?Required	Li's Abbott ARCHITECT 2000 formal contrast was −0.06 mIU/L, 95% CI −0.44~0.31, P = 0.74. Nonsignificance was not converted into absence of bias, equivalence or absence of interference at other exposures. S01 S02	The retained Abbott values from the same specimens were linked to the comparator method's limitations.	Abbott's original comparator method, exposure conditions, paired estimate and CI/P	Verify the original results by distinguishing platform comparisons on the same specimens from time contrasts with pre-exposure/post-washout measurements.
20	Partly verified	Full text not readStored summary read	N20 · Zhang Roche doses and time pointsAt which doses and blood-draw times was lower Roche TSH observed in Zhang?Required	In the same 10 participants, Roche cobas e602 TSH was lower with 5 mg at 2 hours, P = 0.005, and with 10 mg at 2 hours and 8 hours, each P < 0.001. Exact mean differences and CIs are unverified. S04	Direction, dose/time point and P are available, but direct quantitative bias and intervals remain to be verified.	Zhang's original Roche mean differences, variances, CIs, denominators and reported P by time point/dose	Attribute results versus baseline at each dose to their time point/assay, and check whether separate direct estimates exist for comparisons between doses.
21	Partly verified	Full text not readStored summary read	N21 · Zhang platforms with negative findingsWere Zhang's negative TSH observations on Beckman and Abbott preserved by analyte?Required	No interference was observed under the tested conditions for Zhang's Beckman UniCel DxI 800 TSH and Abbott ARCHITECT 2000 TSH. These TSH methods did not use biotin-streptavidin, and interference affecting other thyroid analytes on Beckman was not transferred to TSH. S04	Direction/principle is available for these TSH methods, but exact mean differences, CIs and historical reagent details are unverified.	Each TSH method's reagents/principle, original results by dose/time and separate tables for other analytes	Hold both instrument and analyte fixed and separately compare negative TSH observations with interference results for other analytes.
22	Partly verified	Full text not readStored summary read	N22 · Zhang later blood drawsWas nonsignificance at 26 hours and 50 hours converted into a universal stopping interval?Required	Zhang records that no significant difference versus baseline was reported at 26 hours and 50 hours for either dose. Exact mean differences and CIs are unverified, and this is not interpreted as a universal supplement-stopping interval. S04 S09	Results at the recorded later time points are available, but do not establish bias of 0 or a universal recovery time.	Original results/intervals by blood-draw time, actual dosing/stopping times and duration information by assay/population	Distinguish observations at blood-draw times from criteria for absence of interference, and compare actual persistence/resolution with the original intervals and criteria for those conditions.
23	Partly verified	Full text not readStored summary read	N23 · Ylli abstract-level resultsWas the direction corroborated by Ylli distinguished from unverified quantitative tables?Required	Ylli reported 13 adults, 10 mg/day for 8 days, and measurements on day 1/day 8 before dosing, at 2 hours and at 5 hours. The abstract supports Roche changes and the greatest interference at 2 hours, but full-text quantitative bias is unverified, and percentages from searches were not imported. S05	The abstract's direction and timeline are available, but quantitative tables, exact analysis denominators/CIs remain to be verified.	Ylli's original full-text quantitative tables, TSH analysis n/differences/CIs by time point and the abstract's role	Match the abstract/figure captions to the original tables to distinguish the level of directional verification from numerical verification.
24	Met	Full text not readStored summary read	N24 · Roche document versionWhat are the exact version, product and platforms of the Roche method document?Required	The retained document is Roche Elecsys TSH US 2024-10 V2.0, document 08429324501V2.0, product ref 08429324160. It describes that reagent's performance on cobas e411/e601/e602 and does not verify current laboratory installations. S08	The retained document's identity and scope of applicability were linked. Historical/current reagent equivalence or installation was not certified.	Roche method document version, document/product identifiers, supported platforms and installation/revision data	Link document identifiers to applicable platforms, and separately compare whether the versions at the time of testing/currently installed match.
25	Met	Full text not readStored summary read	N25 · Analytical performance acceptance criteriaWhat do the document's biotin test range and allowable deviations mean?Required	The Roche document specifies a test range of biotin ≤1200 ng/mL. At TSH ≤0.2 µIU/mL, the allowable deviation is ≤0.02 µIU/mL; above that, it is ≤10%. This is an analytical performance document, not an oral safe dose or a guarantee of no interference in all laboratories. S08	The original analytical acceptance values were accurately linked to their nonclinical scope.	The method document's test concentrations, allowable deviations, validation conditions and revision/installation information	Compare the document's concentrations, TSH ranges and allowable deviations, and keep human oral-exposure/clinical-safety questions separate.
26	Met	Full text not readStored summary read	N26 · Published correction and unitsWas Li's published unit correction applied to the original units?Required	Under the 2017-11-21 correction, Li's serum-biotin unit was retained as pg/mL. TSH in mIU/L was unchanged. The S03 correction belongs to the same Li report family and is not an independent human trial. S01 S03	This is a documentation condition linking the retained unit correction to its applicability.	Identity and original wording of the published correction, units before/after correction and locations where it applies	Compare the correction with its linked numbers/units, and do not change values/units outside its applicability.
27	Met	Full text not readStored summary read	N27 · Assigned value above the upper limitIs day 7 biotin of 3601 an actual precisely measured concentration?Required	The day 7 value of 3601 was assigned for analysis because all measurements exceeded 3600. It was not interpreted as an exact measured serum-biotin concentration or an individual dose-concentration relationship. S01 S03	The meaning of the retained upper-limit exceedance and assigned analysis value was verified.	Serum-biotin measurement range, handling of values above the upper limit and the actual analytical assignment rule	Compare the original detection range and assignment handling to distinguish actual observations, values above the upper limit and model inputs.
28	Not applicable	Full text not readStored summary read	N28 · Nonapplicability of other analytesAre results for other thyroid analytes/nonhormone analytes applied to this TSH question?Boundaries for extensions	Interference in other thyroid analytes on Beckman was not transferred to TSH. Nonhormone assay results in the title of the Li paper and the FDA troponin safety document are also not combined as direct numerical evidence of this TSH bias. S01 S04 S07	Direct assessment of other analytes is outside the selected TSH question. This status does not convert Not read into Not applicable.	Analyte-specific result tables within the paper/instrument and the original selected-endpoint boundary	Separate results by analyte-platform-exposure-time point to prevent transferring other endpoints that share the same instrument name.
29	Unverified	Full text not readStored summary read	N29 · Specimen flow and missingnessCan measurements/analyses and missingness be linked by platform and time point?Required	Li's 6 participants and 18 time-point specimens are retained. Zhang's exact analyzed-specimen counts by platform/time point and Ylli's detailed TSH analysis denominators are unverified. The current data were not used to create claims of no missingness/exclusions or a common analysis n. S01 S04 S05	Original data are insufficient to fully link the analysis flow for each platform/time point.	Participant→blood draw→specimen→platform measurement→analysis flow and handling of indeterminate/excluded/missing results	Compare the actual measurement/analysis flow by platform and time point, and do not arbitrarily fill missing results with normal/0.
30	Unverified	Full text not readStored summary read	N30 · Measurement procedures and QCTo what level were measurement procedures, calibration/QC and specimen handling verified?Required	Retained S01/S02/S04 contain historical locations where methods/assay principles were verified. The KO/structure currently read does not embed detailed values for calibration/QC, storage or measurement order/reading, so those procedures were not established. S01 S02 S04	The existence of a verification location differs from the detailed values embedded in the retained summary read in this review.	Assay-specific calibration/QC, specimen collection/storage, measurement order, reading/blinding and original methodological procedures	Compare handling/calibration/measurement conditions for the same specimens to verify procedures that could explain differences between time points/platforms.
31	Unverified	Full text not readStored summary read	N31 · Planning and analysis selectionWere registration, protocol and SAP compared with actual platforms/time points/contrasts?Required	Li's NCT03034707 and Zhang's ChiCTR1800020472 identifiers are retained. Some registration histories, protocols and SAPs, as well as numerical supplements/full tables that were not accessible in the historical record, are currently unverified. Agreement with the original plan or selective reporting was not established. S01 S02 S04 S05	Identifiers and analysis locations alone do not complete the comparison with advance plans/multiplicity.	NCT03034707 and ChiCTR1800020472 histories, protocol/SAP, plans for platforms/endpoints/time points and numerical supplements	Compare registration/plan versions and dates with the contrasts/time points actually reported, distinguishing reasons for changes and handling of multiplicity.
32	Met	Full text not readStored summary read	N32 · Reports and study familiesWere reports, platforms, corrections and method documents counted as independent human replications?Required	F01's Li main article S01, supplement S02 and correction S03 belong to the same family. F02's Zhang S04, F03's Ylli S05 and A01's manufacturer document S08 have distinct roles. Multiple platforms, 12 bibliographic entries and secondary citations in official documents were not counted as 12 human replications. S01 S02 S03 S04 S05 S08	The retained family identities and report roles have been linked. Replication was not calculated from the number of platforms or bibliographic entries.	Report-family-assay/outcome relationships and links to registrations, corrections, method documents and repeat citations	Map unique participant families to report, platform and document types, and assess independence and evidence level separately.
33	Partly verified	Full text not readStored summary read	N33 · Funding, products and independenceTo which report do funding, product provision and author relationships belong?Required	Li records NIH, university and participating-laboratory support and author-specific commercial relationships as disclosed in the original source. Zhang declares no funding/conflicts of interest; this is not independent verification. Ylli's detailed funding and product roles are unverified, and the Roche method document is a manufacturer document. S01 S04 S05 S08	The verification levels of the reports are distinguished, but full comparison against the original detailed declarations and product roles remains outstanding.	Study-specific funding, product roles, author relationships, declarations in manufacturer performance documents, and their original locations	Compare the funding/supply/declarations for the relevant report without transferring them to the independence of another study or the validity of its results.
34	Met	Full text not readStored summary read	N34 · Current and historical readingHas current reading of local summaries been distinguished from historical external access and access dates?Required	The current stored manuscript's 17 KO fields, 4 structured evidence entries and 12 bibliographic entries, plus measurement/display/correction and historical metadata, were read. Historical full text/PDF access, official extracts, abstracts and access failures are historical records. All external materials remain unread in this review; individual access dates are null, and the original review date, 2026-09-15, is separate. S01 S02 S03 S04 S05 S06 S07 S08 S09 S10 S11 S12	This is a record condition that separates materials actually read in the current review from historical access and dates.	Physical material types, URLs, historical access_level/location, report-specific access-date records and actions in this review	Compare each link's actual material type with its historical access level, and record dates/current access events separately.
35	Unverified	Full text not readStored summary read	N35 · Candidates verified only at the metadata levelWere discovery leads for S10/S11/S12 elevated to direct performance figures?Required	S10 ETA2026 is a historical record of metadata discovery only and a failed attempt to access the publisher's full text. The original concentration-response tables for S11 LOCI and the original extraction for S12 routine immunoassays were also unverified at that time. These were not elevated to new access or direct quantitative evidence in this review. S10 S11 S12	The currently retained summaries contain no direct performance or concentration-response information.	Original full texts/concentration-response tables and identity/access records for the S10 guideline, S11 LOCI and S12 clinical-measurement candidates	Link discovered bibliographic records to full-text results without extracting or estimating concentrations/bias figures from tables that were not accessed.
36	Met	Full text not readStored summary read	N36 · Inheritance of general safety sourcesWere the historical NIH/FDA extracts counted as independent TSH studies?Required	NIH S06 and FDA S07 inherit the original sources, extracts and access records from earlier work, with no new search. They are general safety materials and were not counted as independent TSH studies or evidence of the same bias across all analytes. S06 S07	The distinction between official background, historical inheritance and independent replication was verified. The official documents have not been newly read in the current review.	Historical NIH/FDA extracts, original access histories, and the documents' actual scope of analytes/secondary citations	Link safety background/secondary citations in official documents to unique studies and distinguish them from independent results.
37	Partly verified	Full text not readStored summary read	N37 · Guidance and boundaries for stopping intervalsIs AACC guidance distinguished from individual stopping intervals and testing/treatment schedules?Required	S09 AACC2020 guidance is a historical original-source record of mechanisms, assay specificity, renal elimination and recommendations. The original table does not prescribe an individual's supplement stopping interval, testing schedule or treatment change, and prohibits a universal stopping interval. S09	The role of the guidance and scope of action have been linked, but the original recommendation context that is not currently embedded, and individual conditions, have not been verified.	The actual context of guidance recommendations by population, renal function/exposure and assay, and individual testing conditions	Compare assay/population-specific guidance conditions with actual installations and exposure, without generalizing to a universal interval or individual action.
38	Partly verified	Full text not readStored summary read	N38 · Safety Warning and patient harmWhat possibility and what actual observations does the Warning represent?Required	The original safety status is Warning. This reflects the possibility that falsely low TSH could lead to interpretation errors; the direct observations are assay-specific bias and reference-limit crossing. The incidence of actual patient harm is not an established result. S01 S04 S09	The original reason for the Warning and the level of direct observation have been retained. There are no data establishing the frequency/causation of actual harm.	Reference-limit crossing of measured values, actual clinical judgments/actions after testing, and harm definitions/collection/denominators/follow-up	Compare analytical bias separately with the timing, alternative explanations and denominators for post-test decisions and patient events to verify the scope of direct harm evidence.
39	Unverified	Full text not readStored summary read	N39 · Vulnerable populations, high doses and durationHave bias magnitude and duration outside the healthy-adult conditions been verified?Required for extension claims; supplementary to the narrow question	These healthy-adult data did not establish bias magnitude or duration in populations with renal impairment, pregnancy, childhood or high-dose treatment. Do not generalize to individual stopping intervals or long-term safety. S01 S04 S05 S09	The currently retained materials contain no direct measurement information beyond the selected healthy-adult conditions.	Actual exposure, reagents and blood-draw-time-specific bias/duration information for populations defined by renal function, pregnancy, childhood or high-dose treatment	Compare exposure/elimination, underlying conditions and assay/time-point data for special populations, and distinguish them from healthy-adult results.
40	Partly verified	Full text not readStored summary read	N40 · Reference date and update scopeWhich retained reference date underlies the statements, and what changes trigger a new review?Required	The evidence-review date is 2026-09-15, and this retained-material transition is dated 2026-10-05. The original revision_history records the initial measurement-only current value and retains the unit correction. No new search, original-source verification or verification of reagent installations/the latest guidance was performed. S03 S08 S10	The recorded reference date and reasons for updates have been linked, but up-to-date completeness and actual current installations have not been verified.	Reference date, current review date, search/access records, reagent revisions, original corrections/retractions, and new numerical/classification data	Retain before/after original values, versions, dates and access levels under the same ID, and compare the basis for changes and revisions of conditions as separate events.

No items match your search or filter.

40 itemsWhat the statuses mean

Assessment scope

Stored-material review date: 2026-10-05
Original evidence date: 2026-09-15
Scope actually checked: Stored Korean and English manuscripts, bibliography and structure, 40 conditions, and application and review records. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean: This is the date the stored materials were checked, not the date of an up-to-date clinical literature search.
Population: Detailed direct evidence concerns healthy adults; no automatic extension to patients, renal impairment or pregnancy
Ingredient, formulation and route: Biotin · Study-specific biotin supplements; tablet/capsule, exact composition and batch unverified · Oral
Dose: 5 mg/day or 10 mg/day; separated by study, platform and blood sampling time
Comparator: The same participants before exposure and after washout, and comparator platforms on specimens from the same time point; not presented as a randomized placebo trial
Measured outcome: TSH assay bias relative to pre-exposure/post-washout measurements or a biotin-independent method; clinical reference-limit crossing considered separately
Duration: 7 or 8 days of exposure; dosing duration and the interval from the last dose to blood sampling kept separate
Questions outside this scope: Thyroid function/treatment effects, diagnostic accuracy/actual misdiagnosis/patient harm rates, all analytes/reagents, a universal stopping interval, and extensions to safe human doses/special populations are separate questions.

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

S01 · Li et al. 2017. Association of Biotin Ingestion With Performance of Hormone and Nonhormone Assays in Healthy Adults

Source

Material type: Publisher's full HTML text of the original article (historical access)
Materials actually read: The relevant bibliographic entry, summary and structure in the stored manuscript were read. The linked external original materials were not acquired or read in this review.
Findings recorded in the stored summary: Record at the time of retention: 6 healthy adults, 18 time-point specimens, 10 mg/day for 7 days. day 7 was approximately 2 hours after the last dose, and day 14 was 7 days after stopping. The formal contrast day 7 − mean(day 0, day 14) is retained separately for Roche −0.72/CI −1.13~−0.32/P = 0.006, Ortho −1.67/CI −2.08~−1.26/P < 0.001, Vista −0.11/CI −0.49~0.26/P = 0.56 and Abbott −0.06/CI −0.44~0.31/P = 0.74 mIU/L. The historical simple difference between means, −0.59, is separate from the model contrast. Serum-biotin 3601 is an assigned value after the upper limit of 3600 was exceeded. NIH, university and participating-laboratory support/author relationships are records for this study.
Record level: This is a transition of the KO/structured evidence, bibliography and historical access locations retained as of 2026-09-15. It is not external original-source reading, new numerical calculation or reassessment in this review.
Study overlap and independent replication: False

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Publisher's full HTML text of the original article This material	Unverified (no external lookup in this review)	Access not attempted	Not read	The input actually read in this review is the source JSON containing the retained bibliographic entry and Korean summary/structure. No access to this external material type was attempted in this review; it was not acquired or read. This link matches the actual material type of the URL in the currently retained bibliographic entry. Historical access level: publisher_full_text. Methods; Statistical Analysis; Table 1 TSH rows; Table 4; Discussion; Article Information. Report-specific historical access dates are unverified. The stored manuscript's evidence-review date, 2026-09-15, is not the date on which the original material was actually accessed. No access to external material was attempted and no original source was read in this review.
Registration version history Material URL unverified	Unverified (no external lookup in this review)	Access not attempted	Not read	The input actually read in this review is the source JSON containing the retained bibliographic entry and Korean summary/structure. No access to this external material type was attempted in this review; it was not acquired or read. A separate actual URL for this material type is currently unverified. The original bibliographic link is an identifying reference and is not presented as the original source for this material type. Historical access level: publisher_full_text. Methods; Statistical Analysis; Table 1 TSH rows; Table 4; Discussion; Article Information. Report-specific historical access dates are unverified. The stored manuscript's evidence-review date, 2026-09-15, is not the date on which the original material was actually accessed. No access to external material was attempted and no original source was read in this review.
Protocol Material URL unverified	Unverified (no external lookup in this review)	Access not attempted	Not read	The input actually read in this review is the source JSON containing the retained bibliographic entry and Korean summary/structure. No access to this external material type was attempted in this review; it was not acquired or read. A separate actual URL for this material type is currently unverified. The original bibliographic link is an identifying reference and is not presented as the original source for this material type. Historical access level: publisher_full_text. Methods; Statistical Analysis; Table 1 TSH rows; Table 4; Discussion; Article Information. Report-specific historical access dates are unverified. The stored manuscript's evidence-review date, 2026-09-15, is not the date on which the original material was actually accessed. No access to external material was attempted and no original source was read in this review.
Analysis plan (SAP) Material URL unverified	Unverified (no external lookup in this review)	Access not attempted	Not read	The input actually read in this review is the source JSON containing the retained bibliographic entry and Korean summary/structure. No access to this external material type was attempted in this review; it was not acquired or read. A separate actual URL for this material type is currently unverified. The original bibliographic link is an identifying reference and is not presented as the original source for this material type. Historical access level: publisher_full_text. Methods; Statistical Analysis; Table 1 TSH rows; Table 4; Discussion; Article Information. Report-specific historical access dates are unverified. The stored manuscript's evidence-review date, 2026-09-15, is not the date on which the original material was actually accessed. No access to external material was attempted and no original source was read in this review.

S02 · Li et al. 2017 supplementary methods and tables

Source

Material type: Publisher's methods and numerical supplement PDF (historical access)
Materials actually read: The relevant bibliographic entry, summary and structure in the stored manuscript were read. The linked external original materials were not acquired or read in this review.
Findings recorded in the stored summary: Record at the time of retention: eFigure 1 and eTable 1, PDF p6, from the same Li study are historical locations where TSH assay principles and reference intervals were checked. These locations relate to the VITROS lower limit of 0.47 mIU/L and all 6 participants' post-exposure readings below 0.15 mIU/L, nonsignificance at this exposure despite Vista's biotin dependence, and interpretation boundaries for same-specimen comparisons. No independent participants/studies are added.
Record level: This is a transition of the KO/structured evidence, bibliography and historical access locations retained as of 2026-09-15. It is not external original-source reading, new numerical calculation or reassessment in this review.
Study overlap and independent replication: False

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Methods and numerical supplement PDF This material	Unverified (no external lookup in this review)	Access not attempted	Not read	The input actually read in this review is the source JSON containing the retained bibliographic entry and Korean summary/structure. No access to this external material type was attempted in this review; it was not acquired or read. This link matches the actual material type of the URL in the currently retained bibliographic entry. Historical access level: publisher_full_pdf. eFigure 1; eTable 1, PDF p6: TSH assay principles and reference intervals. Report-specific historical access dates are unverified. The stored manuscript's evidence-review date, 2026-09-15, is not the date on which the original material was actually accessed. No access to external material was attempted and no original source was read in this review.

S03 · Incorrect Unit of Measure. JAMA 2017;318(19):1937

Source

Material type: Full HTML text of the published unit correction (historical access)
Materials actually read: The relevant bibliographic entry, summary and structure in the stored manuscript were read. The linked external original materials were not acquired or read in this review.
Findings recorded in the stored summary: Record at the time of retention: The published correction dated 2017-11-21 retains the serum-biotin unit as pg/mL without changing TSH mIU/L. The day 7 value of 3601 is an assignment after the upper limit of 3600 was exceeded, not an actual precisely measured concentration. The correction belongs to the same Li report family and is not a new human replication.
Record level: This is a transition of the KO/structured evidence, bibliography and historical access locations retained as of 2026-09-15. It is not external original-source reading, new numerical calculation or reassessment in this review.
Study overlap and independent replication: False

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Full HTML text of the published unit correction This material	Unverified (no external lookup in this review)	Access not attempted	Not read	The input actually read in this review is the source JSON containing the retained bibliographic entry and Korean summary/structure. No access to this external material type was attempted in this review; it was not acquired or read. This link matches the actual material type of the URL in the currently retained bibliographic entry. Historical access level: publisher_full_text. Correction paragraph published 2017-11-21. Report-specific historical access dates are unverified. The stored manuscript's evidence-review date, 2026-09-15, is not the date on which the original material was actually accessed. No access to external material was attempted and no original source was read in this review.

S04 · Zhang et al. 2020. Assessment of biotin interference in thyroid function tests

Source

Material type: Full text of the original article in a repository (historical access)
Materials actually read: The relevant bibliographic entry, summary and structure in the stored manuscript were read. The linked external original materials were not acquired or read in this review.
Findings recorded in the stored summary: Record at the time of retention: The same 10 healthy adults used 5/10 mg/day for 7 days each in a fixed sequence. Roche TSH was lower at 5 mg, 2 hours, P = 0.005, and at 10 mg, 2/8 hours, each P < 0.001; at 26/50 hours, both doses had nonsignificant comparisons with baseline. Exact mean differences/CI and analyzed specimen counts by platform/time point are unverified. The specified TSH methods on Beckman UniCel DxI 800 and Abbott ARCHITECT 2000 did not use biotin-streptavidin, and interference was not observed under the tested conditions; results for other analytes are not transferred. No funding/conflicts of interest is an author declaration.
Record level: This is a transition of the KO/structured evidence, bibliography and historical access locations retained as of 2026-09-15. It is not external original-source reading, new numerical calculation or reassessment in this review.
Study overlap and independent replication: False

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Full text of the original article in the ResearchGate repository This material	Unverified (no external lookup in this review)	Access not attempted	Not read	The input actually read in this review is the source JSON containing the retained bibliographic entry and Korean summary/structure. No access to this external material type was attempted in this review; it was not acquired or read. This link matches the actual material type of the URL in the currently retained bibliographic entry. Historical access level: primary_article_full_text_on_repository. Medicine 99(9):e19232; sections 2.1–2.3, 3.1–3.3, Table 1 and discussion; Figure 1 timing. Report-specific historical access dates are unverified. The stored manuscript's evidence-review date, 2026-09-15, is not the date on which the original material was actually accessed. No access to external material was attempted and no original source was read in this review.
Registration version history Material URL unverified	Unverified (no external lookup in this review)	Access not attempted	Not read	The input actually read in this review is the source JSON containing the retained bibliographic entry and Korean summary/structure. No access to this external material type was attempted in this review; it was not acquired or read. A separate actual URL for this material type is currently unverified. The original bibliographic link is an identifying reference and is not presented as the original source for this material type. Historical access level: primary_article_full_text_on_repository. Medicine 99(9):e19232; sections 2.1–2.3, 3.1–3.3, Table 1 and discussion; Figure 1 timing. Report-specific historical access dates are unverified. The stored manuscript's evidence-review date, 2026-09-15, is not the date on which the original material was actually accessed. No access to external material was attempted and no original source was read in this review.
Protocol Material URL unverified	Unverified (no external lookup in this review)	Access not attempted	Not read	The input actually read in this review is the source JSON containing the retained bibliographic entry and Korean summary/structure. No access to this external material type was attempted in this review; it was not acquired or read. A separate actual URL for this material type is currently unverified. The original bibliographic link is an identifying reference and is not presented as the original source for this material type. Historical access level: primary_article_full_text_on_repository. Medicine 99(9):e19232; sections 2.1–2.3, 3.1–3.3, Table 1 and discussion; Figure 1 timing. Report-specific historical access dates are unverified. The stored manuscript's evidence-review date, 2026-09-15, is not the date on which the original material was actually accessed. No access to external material was attempted and no original source was read in this review.
Analysis plan (SAP) Material URL unverified	Unverified (no external lookup in this review)	Access not attempted	Not read	The input actually read in this review is the source JSON containing the retained bibliographic entry and Korean summary/structure. No access to this external material type was attempted in this review; it was not acquired or read. A separate actual URL for this material type is currently unverified. The original bibliographic link is an identifying reference and is not presented as the original source for this material type. Historical access level: primary_article_full_text_on_repository. Medicine 99(9):e19232; sections 2.1–2.3, 3.1–3.3, Table 1 and discussion; Figure 1 timing. Report-specific historical access dates are unverified. The stored manuscript's evidence-review date, 2026-09-15, is not the date on which the original material was actually accessed. No access to external material was attempted and no original source was read in this review.

S05 · Ylli et al. 2021. Biotin Interference in Assays for Thyroid Hormones, Thyrotropin and Thyroglobulin

Source

Material type: PubMed abstract and figure captions (historical access)
Materials actually read: The relevant bibliographic entry, summary and structure in the stored manuscript were read. The linked external original materials were not acquired or read in this review.
Findings recorded in the stored summary: Record at the time of retention: 13 adults enrolled, 10 mg/day for 8 days, with measurements on day 1/day 8 before dosing and at 2 hours and 5 hours. The abstract supports Roche TSH changes and the greatest interference at 2 hours. Detailed TSH analysis n, full-text quantitative tables, exact bias/CI and funding/product roles are unverified; percentages from search summaries were not imported.
Record level: This is a transition of the KO/structured evidence, bibliography and historical access locations retained as of 2026-09-15. It is not external original-source reading, new numerical calculation or reassessment in this review.
Study overlap and independent replication: False

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
PubMed abstract and figure captions This material	Unverified (no external lookup in this review)	Access not attempted	Not read	The input actually read in this review is the source JSON containing the retained bibliographic entry and Korean summary/structure. No access to this external material type was attempted in this review; it was not acquired or read. This link matches the actual material type of the URL in the currently retained bibliographic entry. Historical access level: pubmed_abstract_and_figure_captions. Abstract Methods/Results; TSH figure caption; conflicts statement. Report-specific historical access dates are unverified. The stored manuscript's evidence-review date, 2026-09-15, is not the date on which the original material was actually accessed. No access to external material was attempted and no original source was read in this review.
Quantitative tables in the original article's full text Material URL unverified	Unverified (no external lookup in this review)	Access not attempted	Not read	The input actually read in this review is the source JSON containing the retained bibliographic entry and Korean summary/structure. No access to this external material type was attempted in this review; it was not acquired or read. A separate actual URL for this material type is currently unverified. The original bibliographic link is an identifying reference and is not presented as the original source for this material type. Historical access level: pubmed_abstract_and_figure_captions. Abstract Methods/Results; TSH figure caption; conflicts statement. Report-specific historical access dates are unverified. The stored manuscript's evidence-review date, 2026-09-15, is not the date on which the original material was actually accessed. No access to external material was attempted and no original source was read in this review.
Original numerical supplement Material URL unverified	Unverified (no external lookup in this review)	Access not attempted	Not read	The input actually read in this review is the source JSON containing the retained bibliographic entry and Korean summary/structure. No access to this external material type was attempted in this review; it was not acquired or read. A separate actual URL for this material type is currently unverified. The original bibliographic link is an identifying reference and is not presented as the original source for this material type. Historical access level: pubmed_abstract_and_figure_captions. Abstract Methods/Results; TSH figure caption; conflicts statement. Report-specific historical access dates are unverified. The stored manuscript's evidence-review date, 2026-09-15, is not the date on which the original material was actually accessed. No access to external material was attempted and no original source was read in this review.

S06 · NIH Office of Dietary Supplements: Biotin—Health Professional Fact Sheet

Source

Material type: Historically inherited extract from an official NIH web document
Materials actually read: The relevant bibliographic entry, summary and structure in the stored manuscript were read. The linked external original materials were not acquired or read in this review.
Findings recorded in the stored summary: General background record at the time of retention: The scope is inherited original sources/extracts/access records for NIH ODS Table1, risks from excessive biotin and interactions with laboratory tests, refs9/38. No new search was conducted, and this was not counted as an independent TSH study or the same bias across all analytes.
Record level: This is a transition of the KO/structured evidence, bibliography and historical access locations retained as of 2026-09-15. It is not external original-source reading, new numerical calculation or reassessment in this review.
Study overlap and independent replication: False

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Official NIH ODS web document This material	Unverified (no external lookup in this review)	Access not attempted	Not read	The input actually read in this review is the source JSON containing the retained bibliographic entry and Korean summary/structure. No access to this external material type was attempted in this review; it was not acquired or read. This link matches the actual material type of the URL in the currently retained bibliographic entry. Historical access level: inherited_official_extract. Table1; Health Risks from Excessive Biotin; Interactions with Laboratory Tests, refs9/38. Report-specific historical access dates are unverified. The stored manuscript's evidence-review date, 2026-09-15, is not the date on which the original material was actually accessed. No access to external material was attempted and no original source was read in this review.

S07 · FDA: Biotin Interference with Troponin Lab Tests—Assays Subject to Biotin Interference

Source

Material type: Historically inherited extract from an official FDA web document
Materials actually read: The relevant bibliographic entry, summary and structure in the stored manuscript were read. The linked external original materials were not acquired or read in this review.
Findings recorded in the stored summary: General background record at the time of retention: The opening safety statement and paragraphs on residual assay interference in the FDA troponin-testing document are inherited from an earlier extraction. This is not elevated to a new search or original-source reading in this review, or to independent TSH figures/studies.
Record level: This is a transition of the KO/structured evidence, bibliography and historical access locations retained as of 2026-09-15. It is not external original-source reading, new numerical calculation or reassessment in this review.
Study overlap and independent replication: False

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Official FDA web document on troponin tests This material	Unverified (no external lookup in this review)	Access not attempted	Not read	The input actually read in this review is the source JSON containing the retained bibliographic entry and Korean summary/structure. No access to this external material type was attempted in this review; it was not acquired or read. This link matches the actual material type of the URL in the currently retained bibliographic entry. Historical access level: inherited_official_extract. Opening safety statement and paragraphs on residual assay interference. Report-specific historical access dates are unverified. The stored manuscript's evidence-review date, 2026-09-15, is not the date on which the original material was actually accessed. No access to external material was attempted and no original source was read in this review.

S08 · Roche Elecsys TSH method sheet, US, 2024-10 V2.0

Source

Material type: Official Roche reagent method PDF (historical access)
Materials actually read: The relevant bibliographic entry, summary and structure in the stored manuscript were read. The linked external original materials were not acquired or read in this review.
Findings recorded in the stored summary: Record at the time of retention: US 2024-10 V2.0, 08429324501V2.0, product ref 08429324160 is a method document for cobas e411/e601/e602. For biotin ≤1200 ng/mL, at TSH ≤0.2 µIU/mL the deviation criterion is ≤0.02 µIU/mL; at higher TSH it is ≤10%. This is a manufacturer analytical document. It does not guarantee a safe oral dose in humans or bias 0, verify every laboratory's installed version, or establish identity with historical reagents.
Record level: This is a transition of the KO/structured evidence, bibliography and historical access locations retained as of 2026-09-15. It is not external original-source reading, new numerical calculation or reassessment in this review.
Study overlap and independent replication: False

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Official Roche reagent method PDF This material	Unverified (no external lookup in this review)	Access not attempted	Not read	The input actually read in this review is the source JSON containing the retained bibliographic entry and Korean summary/structure. No access to this external material type was attempted in this review; it was not acquired or read. This link matches the actual material type of the URL in the currently retained bibliographic entry. Historical access level: official_full_pdf. PDF p1 product/platform/test principle; pp2–3 Limitations–interference; p3 measurement range. Report-specific historical access dates are unverified. The stored manuscript's evidence-review date, 2026-09-15, is not the date on which the original material was actually accessed. No access to external material was attempted and no original source was read in this review.

S09 · AACC Academy guidance: Biotin Interference in Laboratory Tests

Source

Material type: Full HTML text of official AACC guidance (historical access)
Materials actually read: The relevant bibliographic entry, summary and structure in the stored manuscript were read. The linked external original materials were not acquired or read in this review.
Findings recorded in the stored summary: General background record at the time of retention: This is a historical record of checking the locations of mechanisms, assay specificity, renal elimination and recommendations in the 2020-01-13 AACC guidance. Numerical recommendations not embedded in the current JSON are not newly presented or used as individual stopping intervals, testing schedules or treatment changes.
Record level: This is a transition of the KO/structured evidence, bibliography and historical access locations retained as of 2026-09-15. It is not external original-source reading, new numerical calculation or reassessment in this review.
Study overlap and independent replication: False

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Full HTML text of official AACC guidance This material	Unverified (no external lookup in this review)	Access not attempted	Not read	The input actually read in this review is the source JSON containing the retained bibliographic entry and Korean summary/structure. No access to this external material type was attempted in this review; it was not acquired or read. This link matches the actual material type of the URL in the currently retained bibliographic entry. Historical access level: official_full_text. 2020-01-13 guidance; mechanisms, assay specificity, renal elimination and recommendations. Report-specific historical access dates are unverified. The stored manuscript's evidence-review date, 2026-09-15, is not the date on which the original material was actually accessed. No access to external material was attempted and no original source was read in this review.

S10 · 2026 ETA guideline on interference in immunoassay measurements used in assessment of thyroid function

Source

Material type: PubMed bibliographic record; historical record of full-text non-access
Materials actually read: The relevant bibliographic entry, summary and structure in the stored manuscript were read. The linked external original materials were not acquired or read in this review.
Findings recorded in the stored summary: Record at the time of retention: Guideline metadata for DOI 10.1530/ETJ-26-0011, PMID 42466561 were discovered, but the publisher full-text request failed at that time. No current access was attempted, and no detailed performance figures/new recommendations were generated from the guideline.
Record level: This is a transition of the KO/structured evidence, bibliography and historical access locations retained as of 2026-09-15. It is not external original-source reading, new numerical calculation or reassessment in this review.
Study overlap and independent replication: False

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
PubMed bibliographic record for the guideline This material	Unverified (no external lookup in this review)	Access not attempted	Not read	The input actually read in this review is the source JSON containing the retained bibliographic entry and Korean summary/structure. No access to this external material type was attempted in this review; it was not acquired or read. This link matches the actual material type of the URL in the currently retained bibliographic entry. Historical access level: metadata_discovered_full_text_inaccessible. Search metadata only; publisher full text request failed. Report-specific historical access dates are unverified. The stored manuscript's evidence-review date, 2026-09-15, is not the date on which the original material was actually accessed. No access to external material was attempted and no original source was read in this review.
Publisher's full text of the guideline Material URL unverified	Unverified (no external lookup in this review)	Access not attempted	Not read	The input actually read in this review is the source JSON containing the retained bibliographic entry and Korean summary/structure. No access to this external material type was attempted in this review; it was not acquired or read. A separate actual URL for this material type is currently unverified. The original bibliographic link is an identifying reference and is not presented as the original source for this material type. Historical access level: metadata_discovered_full_text_inaccessible. Search metadata only; publisher full text request failed. Report-specific historical access dates are unverified. The stored manuscript's evidence-review date, 2026-09-15, is not the date on which the original material was actually accessed. No access to external material was attempted and no original source was read in this review.

S11 · Biotin interference in TSH, FT4, and FT3 assays based on the LOCI technology: identifying interference by dilution

Source

Material type: PMC entry URL for the original article; historical search metadata only
Materials actually read: The relevant bibliographic entry, summary and structure in the stored manuscript were read. The linked external original materials were not acquired or read in this review.
Findings recorded in the stored summary: Record at the time of retention: The candidate identified by DOI 10.1002/jcla.22667, PMCID PMC6818550 concerns LOCI TSH/FT4/FT3 and is limited to discovery metadata. Historical full-text access limitations left the original concentration-response tables unverified, and the PMC original text was not opened in this review.
Record level: This is a transition of the KO/structured evidence, bibliography and historical access locations retained as of 2026-09-15. It is not external original-source reading, new numerical calculation or reassessment in this review.
Study overlap and independent replication: False

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Full HTML text of the original article on PMC (not read in the current review) This material	Unverified (no external lookup in this review)	Access not attempted	Not read	The input actually read in this review is the source JSON containing the retained bibliographic entry and Korean summary/structure. No access to this external material type was attempted in this review; it was not acquired or read. This link matches the actual material type of the URL in the currently retained bibliographic entry. Historical access level: search_metadata_only_full_text_inaccessible. Discovery metadata; no primary concentration-response table verified. Report-specific historical access dates are unverified. The stored manuscript's evidence-review date, 2026-09-15, is not the date on which the original material was actually accessed. No access to external material was attempted and no original source was read in this review.

S12 · Biotin interference in routine clinical immunoassays

Source

Material type: PMC entry URL for the original article; historical search metadata only
Materials actually read: The relevant bibliographic entry, summary and structure in the stored manuscript were read. The linked external original materials were not acquired or read in this review.
Findings recorded in the stored summary: Record at the time of retention: The candidate with DOI 10.1016/j.plabm.2025.e00472, PMCID PMC12099460 is limited to discovery metadata. The record states that a PMC challenge blocked original extraction at that time; this is not an access failure in this review. No quantitative bias, denominators or independent study identities were newly generated.
Record level: This is a transition of the KO/structured evidence, bibliography and historical access locations retained as of 2026-09-15. It is not external original-source reading, new numerical calculation or reassessment in this review.
Study overlap and independent replication: False

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Full HTML text of the original article on PMC (not read in the current review) This material	Unverified (no external lookup in this review)	Access not attempted	Not read	The input actually read in this review is the source JSON containing the retained bibliographic entry and Korean summary/structure. No access to this external material type was attempted in this review; it was not acquired or read. This link matches the actual material type of the URL in the currently retained bibliographic entry. Historical access level: search_metadata_only_full_text_inaccessible. Discovery metadata; PMC challenge prevented primary extraction. Report-specific historical access dates are unverified. The stored manuscript's evidence-review date, 2026-09-15, is not the date on which the original material was actually accessed. No access to external material was attempted and no original source was read in this review.

Report counts versus independent study counts

F01 (S01, S02, S03): Direct oral-exposure and serum-TSH measurement evidence; not used for efficacy scoring. This is the same data family in the existing evidence. Supplements/corrections/platforms, time points and doses are not added as independent participants/studies. / F02 (S04): Direct oral-exposure measurement evidence; interpreted only by time point and platform. This is the same data family in the existing evidence. Supplements/corrections/platforms, time points and doses are not added as independent participants/studies. / F03 (S05): Directional corroboration; full-text quantitative tables unverified. This is the same data family in the existing evidence. Supplements/corrections/platforms, time points and doses are not added as independent participants/studies. / A01 (S08): For checking the current reagent-version boundary; not counted as an independent human replication. This is the existing manufacturer analytical-document family. It is not counted as human participants/independent replication. The 12 bibliographic entries, multiple platforms, doses, time points, supplements and correction documents are not added together as independent human replications. The abstract level of F03 is distinguished from the manufacturer analytical document A01, and the total number of unique analyzed participants remains unverified.

Review criteria

Version NGM-v3106-ORAL-BIOTIN-TSH-MEASUREMENT-1.0 · Criteria record date 2026-10-05. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · Does this table address a measurement question and prevent the application of efficacy grades and scores?

Required materials and conditions: Measurement-only classification, fields marking efficacy as not applicable, and a display contract prohibiting efficacy badges/aggregate ratings/a universal stopping interval
Conditions for verification: Preserve measurement_only, the measurement type, the non-applicability of efficacy grade/score/axes, and the original display_contract unchanged.
Requirement and applicability: Required
Application exceptions: The original grade ?·score null and document quality B are historical values. Blue in the condition status indicates verification of a narrow documentation condition, not an efficacy badge.
Why this condition is needed: This is needed to prevent falsely low measurements from being recast as treatment effects or an aggregate grade.
Referenced methods: C01: Question clarification principles in M03 §3.1, §3.2.1–3.2.4; the detailed separation rules are internally designed / C09: M04 §4.5, §4.6.3; limits on the current data transformation follow the user-defined scope and are internally designed / D01: Chamgap's own diagnostic condition; M03 question/population principles serve only as general references. Reason for application to the measurement family: This is needed to prevent falsely low measurements from being recast as treatment effects or an aggregate grade. This is not a formal implementation of diagnostic/QUADAS/STARD·RoB/GRADE/causality methods or clinical certification.

N02 · Which exposure, specimen, comparison and measurement outcome are brought together in one table?

Required materials and conditions: The original claim and a fixed question specified by healthy adults, oral exposure, serum TSH, platform/reagent, dose and blood sampling time
Conditions for verification: Fix the oral exposure, serum TSH, assay-specific falsely low readings and actual within-person/same-specimen comparisons, and distinguish questions that extend beyond them.
Requirement and applicability: Required
Application exceptions: Even when some concepts from the diagnostic accuracy family are used as references, the question is not changed into one about sensitivity/specificity or a clinical treatment trial.
Why this condition is needed: This is needed to avoid conflating thyroid disease, other analytes and all test interference with this TSH measurement bias.
Referenced methods: C01: Question clarification principles in M03 §3.1, §3.2.1–3.2.4; the detailed separation rules are internally designed / C04: M03 §3.2.1; detailed population conditions are internally designed / C05: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed / C06: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed / D01: Chamgap's own diagnostic condition; M03 question/population principles serve only as general references / D09: Chamgap's own boundary for diagnostic extensions; formal diagnostic methodology evidence has not been reviewed / E09: M03 §3.2.4; internally designed boundary for extensions. Reason for application to the measurement family: This is needed to avoid conflating thyroid disease, other analytes and all test interference with this TSH measurement bias. This is not a formal implementation of diagnostic/QUADAS/STARD·RoB/GRADE/causality methods or clinical certification.

N03 · Which TSH measure in which specimen does the observed outcome represent?

Required materials and conditions: Serum TSH analyte, units, time-point/contrast definitions, and separate blood biotin units
Conditions for verification: Assign assay-specific serum TSH time-point means, formal contrasts and reference-limit crossings to their respective original units/time points.
Requirement and applicability: Required
Application exceptions: Keep blood biotin in pg/mL and reagent-document values in ng/mL, and TSH in mIU/L and document values in µIU/mL, each in its original units. No new conversions are performed.
Why this condition is needed: This is needed to avoid substituting blood biotin concentrations, TSH measurements or disease status for one another.
Referenced methods: C06: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed / D03: Chamgap's own diagnostic condition; formal diagnostic methodology evidence has not been reviewed. Reason for application to the measurement family: This is needed to avoid substituting blood biotin concentrations, TSH measurements or disease status for one another. This is not a formal implementation of diagnostic/QUADAS/STARD·RoB/GRADE/causality methods or clinical certification.

N04 · Are the actual form, batch and total exposure to the biotin supplement known?

Required materials and conditions: Exact chemical form, formulation, batch, purity and dosing records for the study product, and total dietary exposure data
Conditions for verification: Distinguish each study's supplement exposure from unverified product/dietary details.
Requirement and applicability: Required
Application exceptions: Unverified manufacturing source, chemical form, tablet/capsule, batch and dietary exposure do not constitute a finding that a particular product is defective.
Why this condition is needed: This is needed to avoid extending the name biotin and the nominal dose to the composition, purity and actual intake of all supplements.
Referenced methods: C05: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed / H05: Design considerations in M19 §19.2.2–19.2.4; detailed confounding records are internally designed. Reason for application to the measurement family: This is needed to avoid extending the name biotin and the nominal dose to the composition, purity and actual intake of all supplements. This is not a formal implementation of diagnostic/QUADAS/STARD·RoB/GRADE/causality methods or clinical certification.

N05 · Were dosing duration and the interval from the last dose to blood sampling distinguished?

Required materials and conditions: Nominal oral dose, dosing start/end, actual last dose and blood sampling times for each trial
Conditions for verification: Retain the oral dose, dosing duration, assessment day and post-dose blood sampling time for Li, Zhang and Ylli separately by study.
Requirement and applicability: Required
Application exceptions: The tested 5/10 mg doses are not interpreted as safe doses, optimal doses or personal dosing/stopping instructions.
Why this condition is needed: This is needed to avoid treating 7-day/8-day exposure and blood sampling after 2 hours/5 hours/8 hours as the same timeline.
Referenced methods: C05: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed / C06: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed / H02: Design-specific harm questions in M19 §19.2; details of temporal relationships are internally designed / E08: M03 §3.2.1–3.2.4; details of dose, duration and effect modification are internally designed. Reason for application to the measurement family: This is needed to avoid treating 7-day/8-day exposure and blood sampling after 2 hours/5 hours/8 hours as the same timeline. This is not a formal implementation of diagnostic/QUADAS/STARD·RoB/GRADE/causality methods or clinical certification.

N06 · To which populations can the measurements in healthy adults be applied?

Required materials and conditions: Recruitment/selection, baseline thyroid/renal function, age/sex composition and special-population data for each trial
Conditions for verification: Distinguish each study's actually reported population from unverified selection/baseline characteristics and limitations concerning special populations.
Requirement and applicability: Required
Application exceptions: The description of participants as healthy adults alone does not verify recruitment representativeness, sex/age composition and exclusion criteria in full.
Why this condition is needed: This is needed to avoid extending a small sample of healthy people to all patients, people with renal impairment, pregnant people, children and high-dose treatment groups.
Referenced methods: C04: M03 §3.2.1; detailed population conditions are internally designed / D02: Chamgap's own diagnostic sampling condition; formal diagnostic methodology evidence has not been reviewed / H08: M19 §19.1.2–19.2.4; internal application. Reason for application to the measurement family: This is needed to avoid extending a small sample of healthy people to all patients, people with renal impairment, pregnant people, children and high-dose treatment groups. This is not a formal implementation of diagnostic/QUADAS/STARD·RoB/GRADE/causality methods or clinical certification.

N07 · What denominators do Li's 6 people and 18 time-point specimens represent?

Required materials and conditions: Li's participant count, time-point specimen count, and measurement/analysis and exclusion flow by platform
Conditions for verification: Distinguish repeated measurements within the same 6 people from the 18 time-point specimens, and retain gaps in the actual analysis flow.
Requirement and applicability: Required
Application exceptions: Verification of 18 specimens does not mean that missingness and exclusion flows were verified for every assay/time point.
Why this condition is needed: This is needed to avoid overstating sample size and precision by counting repeated specimens as independent participants.
Referenced methods: C07: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed / D06: Chamgap's own diagnostic condition; formal diagnostic methodology evidence has not been reviewed. Reason for application to the measurement family: This is needed to avoid overstating sample size and precision by counting repeated specimens as independent participants. This is not a formal implementation of diagnostic/QUADAS/STARD·RoB/GRADE/causality methods or clinical certification.

N08 · Do Zhang's two doses represent trials with different groups of 10 people each?

Required materials and conditions: Identity of the same participants, exposure order and duration, and analysis flow by dose/platform/time point
Conditions for verification: Retain the same 10 people, the fixed sequence of 7 days each, and the unverified numbers of analyzed specimens by platform/time point.
Requirement and applicability: Required
Application exceptions: The results at the two doses are not recast as a randomized dose comparison or an estimate of interaction between doses.
Why this condition is needed: This is needed to avoid counting fixed-sequence exposures in the same participants as 20 people or two independent trials.
Referenced methods: C02: Distinction between studies and reports in M04 §4.6.1–4.6.2; cohort/outcome linkage is an internal application / C07: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed / D06: Chamgap's own diagnostic condition; formal diagnostic methodology evidence has not been reviewed. Reason for application to the measurement family: This is needed to avoid counting fixed-sequence exposures in the same participants as 20 people or two independent trials. This is not a formal implementation of diagnostic/QUADAS/STARD·RoB/GRADE/causality methods or clinical certification.

N09 · Do Ylli's 13 people constitute the analysis denominator for every TSH value?

Required materials and conditions: Ylli's enrollment/completion/TSH analysis denominators, and specimen flow for each original quantitative table and figure
Conditions for verification: Distinguish the enrollment of 13 adults and the scope of the abstract/figure captions from the unverified detailed TSH analysis denominators.
Requirement and applicability: Required
Application exceptions: Retain the direction reported in the figure captions and abstract, without reconstructing quantitative full-text tables that could not be accessed.
Why this condition is needed: This is needed to avoid automatically inserting the enrollment count in the abstract as the analysis denominator for full-text tables.
Referenced methods: C07: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed / D06: Chamgap's own diagnostic condition; formal diagnostic methodology evidence has not been reviewed / C03: Data collection/selection principles in M04 §4.5–4.6; the separation of access and reading and the hyperlink contract are internally designed. Reason for application to the measurement family: This is needed to avoid automatically inserting the enrollment count in the abstract as the analysis denominator for full-text tables. This is not a formal implementation of diagnostic/QUADAS/STARD·RoB/GRADE/causality methods or clinical certification.

N10 · What comparisons does the actual design provide, and what does it fail to control?

Required materials and conditions: Actual exposure order, concurrent changes, control of background factors, and measurement/reading conditions
Conditions for verification: Retain Li's nonrandomized repeated measurements, Zhang's fixed sequence and Ylli's prospective within-person comparison, along with limitations concerning time/concurrent changes.
Requirement and applicability: Required
Application exceptions: Direct measurement results are not removed merely because the design is nonrandomized. The existence of a clinical RCT is not an essential prerequisite for measurement bias.
Why this condition is needed: This is needed to avoid presenting within-person exposure comparisons as randomized placebo efficacy trials.
Referenced methods: E01: M08 §8.1–8.2.3; internal application / E04: M08 §8.2.2, M15 §15.3.1; internal application / D05: Chamgap's own diagnostic condition; formal diagnostic methodology evidence has not been reviewed / H05: Design considerations in M19 §19.2.2–19.2.4; detailed confounding records are internally designed. Reason for application to the measurement family: This is needed to avoid presenting within-person exposure comparisons as randomized placebo efficacy trials. This is not a formal implementation of diagnostic/QUADAS/STARD·RoB/GRADE/causality methods or clinical certification.

N11 · What comparison references do pre-exposure/post-washout measurements and other platforms provide?

Required materials and conditions: Definitions of time contrasts, and analytical principles and traceability/reference-method information for comparisons using the same specimens
Conditions for verification: Link within-person time contrasts and comparator platforms using specimens from the same time point separately, and explain the limitations of the reference methods.
Requirement and applicability: Required
Application exceptions: Even a biotin-independent method does not automatically establish an independent physiological TSH true value or a gold standard for clinical disease.
Why this condition is needed: This is needed to avoid confusing differences between assays with established diagnostic criteria for patients' thyroid conditions.
Referenced methods: C05: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed / C06: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed / D04: Chamgap's own diagnostic condition; formal diagnostic methodology evidence has not been reviewed / E04: M08 §8.2.2, M15 §15.3.1; internal application. Reason for application to the measurement family: This is needed to avoid confusing differences between assays with established diagnostic criteria for patients' thyroid conditions. This is not a formal implementation of diagnostic/QUADAS/STARD·RoB/GRADE/causality methods or clinical certification.

N12 · Were the principles and instrument identities of the TSH assays distinguished?

Required materials and conditions: Instruments, reagents, principles, specimen procedures and interference tolerance thresholds for each analyte
Conditions for verification: Link the TSH results from Roche, Ortho, Siemens, Abbott and Beckman separately to the level of verification of their principles/versions.
Requirement and applicability: Required
Application exceptions: Vista uses a biotin-dependent TSH assay, yet there was no significant difference at the exposure tested. A positive finding is not assigned on the basis of the principle alone.
Why this condition is needed: This is needed to avoid treating interference on all instruments as identical solely because methods are described as sandwich or biotin-dependent.
Referenced methods: C05: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed / C06: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed / D03: Chamgap's own diagnostic condition; formal diagnostic methodology evidence has not been reviewed / E03: M08 Table 8.2.a, M03 §3.2.4; internal application. Reason for application to the measurement family: This is needed to avoid treating interference on all instruments as identical solely because methods are described as sandwich or biotin-dependent. This is not a formal implementation of diagnostic/QUADAS/STARD·RoB/GRADE/causality methods or clinical certification.

N13 · Are historical tests and current reagents with the same instrument name being treated as identical?

Required materials and conditions: Reagent lots and method versions at the time of the trial, revision histories and actual laboratory installation records
Conditions for verification: Separate the unverified historical reagents/lots from the known identity of the 2024-10 V2.0 document.
Requirement and applicability: Required
Application exceptions: The existence of a Roche 2024 document does not verify actual installations in individual laboratories or equivalence to historical lots.
Why this condition is needed: This is needed to avoid automatically transferring interference in historical trials to revised reagents or the versions currently installed in all laboratories.
Referenced methods: C05: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed / D03: Chamgap's own diagnostic condition; formal diagnostic methodology evidence has not been reviewed / D08: Chamgap's own diagnostic applicability condition; M04 principles distinguishing reports/studies serve as general references / C09: M04 §4.5, §4.6.3; limits on the current data transformation follow the user-defined scope and are internally designed. Reason for application to the measurement family: This is needed to avoid automatically transferring interference in historical trials to revised reagents or the versions currently installed in all laboratories. This is not a formal implementation of diagnostic/QUADAS/STARD·RoB/GRADE/causality methods or clinical certification.

N14 · Which repeated-measures contrast does Li's formal estimate represent?

Required materials and conditions: Formal repeated-measures contrast formula and model, and original estimates/CI/P for each platform
Conditions for verification: Link the within-person repeated-measures contrast day 7 − mean(day 0, day 14) to the estimates for each platform.
Requirement and applicability: Required
Application exceptions: The formal 95% CI is not converted to SD or SE, and no model is newly fitted without the original data.
Why this condition is needed: This is needed to avoid confusing the simple difference obtained by subtracting the day 7 mean from the baseline mean with the formal contrast in the original model.
Referenced methods: C06: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed / E04: M08 §8.2.2, M15 §15.3.1; internal application / E05: M15 §15.3.1–15.3.3; internal application. Reason for application to the measurement family: This is needed to avoid confusing the simple difference obtained by subtracting the day 7 mean from the baseline mean with the formal contrast in the original model. This is not a formal implementation of diagnostic/QUADAS/STARD·RoB/GRADE/causality methods or clinical certification.

N15 · Were Li Roche's formal bias and historical simple difference distinguished?

Required materials and conditions: Li Roche TSH time-point means, formal contrast, original CI/P and display of historical arithmetic
Conditions for verification: Link 1.80→1.21→2.06 and the formal −0.72/CI/P only to Roche cobas e602 and the corresponding time points.
Requirement and applicability: Required
Application exceptions: −0.59 is the historical simple difference in the manuscript, not a new calculation in this review. It is not combined with the formal CI.
Why this condition is needed: This is needed to avoid treating values from different contrast definitions as an error requiring correction or as the same estimate.
Referenced methods: C06: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed / C07: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed / E04: M08 §8.2.2, M15 §15.3.1; internal application / E05: M15 §15.3.1–15.3.3; internal application / C08: M04 §4.6.3, M15 §15.3.1–15.3.3; status separation is internally designed. Reason for application to the measurement family: This is needed to avoid treating values from different contrast definitions as an error requiring correction or as the same estimate. This is not a formal implementation of diagnostic/QUADAS/STARD·RoB/GRADE/causality methods or clinical certification.

N16 · What is the scope of Li's VITROS values and observations relative to the lower reference limit?

Required materials and conditions: VITROS time-point means, formal contrast/CI/P and the method's lower reference limit
Conditions for verification: Preserve the means, formal contrast, CI/P and original lower reference limit for Ortho VITROS 5600.
Requirement and applicability: Required
Application exceptions: The fact that all 6 participants were below the lower limit is an observation in a small measurement sample, not a population frequency.
Why this condition is needed: This is needed to avoid turning platform-specific bias magnitudes and lower-limit crossings into findings for other assays or clinical disease incidence.
Referenced methods: C06: M03 §3.2.4, M15 §15.3.1–15.3.3; outcome adaptations for each question are internally designed / E04: M08 §8.2.2, M15 §15.3.1; internal application / E05: M15 §15.3.1–15.3.3; internal application / D03: Chamgap's internally designed diagnostic condition; formal diagnostic-method evidence not reviewed. Reason for application to the measurement family: This is needed to avoid turning platform-specific bias magnitudes and lower-limit crossings into findings for other assays or clinical disease incidence. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality assessments, or clinical certification.

N17 · Was crossing the lower reference limit expressed as sensitivity, specificity or an actual misdiagnosis rate?

Required materials and conditions: The method's reference limit, individual measurements and actual clinical assessments/follow-up outcome data
Conditions for verification: Separate lower-limit crossings under the test conditions from clinical disease, misdiagnosis and harm rates, and diagnostic accuracy.
Requirement and applicability: Required
Application exceptions: A measurement-bias question does not unconditionally require disease TP/FP/FN/TN tables or clinical outcome trials.
Why this condition is needed: This is needed to distinguish an observation of assay values crossing the lower limit from the frequency of diagnoses/harms in patients.
Referenced methods: D03: Chamgap's internally designed diagnostic condition; formal diagnostic-method evidence not reviewed / D07: Chamgap's internally designed diagnostic-outcome condition; formal diagnostic-method evidence not reviewed / D09: Chamgap's internally designed boundary for diagnostic extensions; formal diagnostic-method evidence not reviewed / H04: M19 §19.1.2–19.2.4; internal application / H09: Chamgap's internally designed interpretation boundary. References M19 principles; not implementation of a formal causality tool. Reason for application to the measurement family: This is needed to distinguish an observation of assay values crossing the lower limit from the frequency of diagnoses/harms in patients. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality assessments, or clinical certification.

N18 · Was the nonsignificant result for biotin-dependent Vista also preserved?

Required materials and conditions: Vista's original assay principle, paired estimate, CI/P and the exposure conditions
Conditions for verification: Preserve the Vista formal contrast and CI/P from the same Li specimens together with its biotin-dependent principle.
Requirement and applicability: Required
Application exceptions: P = 0.56 does not verify equivalence or absence of bias.
Why this condition is needed: This is needed to avoid deleting a negative result that appears inconsistent with the principle or converting it into an effect of 0.
Referenced methods: C08: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is internally designed / E05: M15 §15.3.1–15.3.3; internal application / D03: Chamgap's internally designed diagnostic condition; formal diagnostic-method evidence not reviewed. Reason for application to the measurement family: This is needed to avoid deleting a negative result that appears inconsistent with the principle or converting it into an effect of 0. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality assessments, or clinical certification.

N19 · Was Li's nonsignificant Abbott estimate kept within the scope of the comparator method?

Required materials and conditions: Abbott's original comparator method, exposure conditions, paired estimate and CI/P
Conditions for verification: Attribute the Abbott ARCHITECT 2000 formal contrast, interval and P to the same Li specimens.
Requirement and applicability: Required
Application exceptions: Do not count another assay on the same specimens as an additional human trial or independent participants.
Why this condition is needed: This is needed to avoid extending a negative observation on the comparator platform into a guarantee of no interference under all conditions.
Referenced methods: C08: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is internally designed / D04: Chamgap's internally designed diagnostic condition; formal diagnostic-method evidence not reviewed / E05: M15 §15.3.1–15.3.3; internal application. Reason for application to the measurement family: This is needed to avoid extending a negative observation on the comparator platform into a guarantee of no interference under all conditions. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality assessments, or clinical certification.

N20 · At which doses and blood-draw times was lower Roche TSH observed in Zhang?

Required materials and conditions: Zhang's original Roche mean differences, variances, CIs, denominators and reported P by time point/dose
Conditions for verification: Preserve the reported P and decreases by dose/time point in the same 10 participants, leaving unverified estimates unverified.
Requirement and applicability: Required
Application exceptions: Exact mean differences and CIs are unverified. Do not extract new values from graphs or search summaries.
Why this condition is needed: This is needed to avoid turning the direction associated with a P value into a quantitative bias magnitude or a direct effect between doses.
Referenced methods: C06: M03 §3.2.4, M15 §15.3.1–15.3.3; outcome adaptations for each question are internally designed / E05: M15 §15.3.1–15.3.3; internal application / E08: M03 §3.2.1–3.2.4; dose, duration and effect-modification details are internally designed / H02: design-specific harm questions in M19 §19.2; temporal-relationship details are internally designed. Reason for application to the measurement family: This is needed to avoid turning the direction associated with a P value into a quantitative bias magnitude or a direct effect between doses. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality assessments, or clinical certification.

N21 · Were Zhang's negative TSH observations on Beckman and Abbott preserved by analyte?

Required materials and conditions: Each TSH method's reagents/principle, original results by dose/time and separate tables for other analytes
Conditions for verification: Distinguish the negative observations and principles for Beckman UniCel DxI 800 and Abbott ARCHITECT 2000 TSH.
Requirement and applicability: Required
Application exceptions: Nonuse of biotin-streptavidin is retained information about those TSH methods, not a guarantee for all instruments/versions.
Why this condition is needed: This is needed to avoid transferring interference in other thyroid analytes on the same instrument to TSH results.
Referenced methods: C08: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is internally designed / C06: M03 §3.2.4, M15 §15.3.1–15.3.3; outcome adaptations for each question are internally designed / D03: Chamgap's internally designed diagnostic condition; formal diagnostic-method evidence not reviewed / D08: Chamgap's internally designed diagnostic-applicability condition; general reference to M04 principles for distinguishing reports/studies. Reason for application to the measurement family: This is needed to avoid transferring interference in other thyroid analytes on the same instrument to TSH results. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality assessments, or clinical certification.

N22 · Was nonsignificance at 26 hours and 50 hours converted into a universal stopping interval?

Required materials and conditions: Original results/intervals by blood-draw time, actual dosing/stopping times and duration information by assay/population
Conditions for verification: Preserve reports of nonsignificance versus baseline at 26/50 hours for both doses only within the original conditions.
Requirement and applicability: Required
Application exceptions: Time points after exposure stops are not recommendations for individuals to stop taking the supplement. Nonsignificance is not equivalence either.
Why this condition is needed: This is needed to avoid extending nonsignificance at tested time points into the time when interference ends for all people, doses and assays.
Referenced methods: C08: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is internally designed / E08: M03 §3.2.1–3.2.4; dose, duration and effect-modification details are internally designed / H02: design-specific harm questions in M19 §19.2; temporal-relationship details are internally designed. Reason for application to the measurement family: This is needed to avoid extending nonsignificance at tested time points into the time when interference ends for all people, doses and assays. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality assessments, or clinical certification.

N23 · Was the direction corroborated by Ylli distinguished from unverified quantitative tables?

Required materials and conditions: Ylli's original full-text quantitative tables, TSH analysis n/differences/CIs by time point and the abstract's role
Conditions for verification: Record 10 mg/day, 8 days, day 1/day 8, predose/2/5 hours and the Roche direction within the scope of the abstract.
Requirement and applicability: Required
Application exceptions: Do not import percentages from search summaries. The existence of a PMCID does not mean the full text was read.
Why this condition is needed: This is needed to avoid filling in the direction in the abstract/figure captions with percentages/bias magnitudes from full-text tables.
Referenced methods: C03: data collection/selection principles in M04 §4.5–4.6; separation of access from reading and the hyperlink contract are internally designed / C06: M03 §3.2.4, M15 §15.3.1–15.3.3; outcome adaptations for each question are internally designed / E05: M15 §15.3.1–15.3.3; internal application / D08: Chamgap's internally designed diagnostic-applicability condition; general reference to M04 principles for distinguishing reports/studies. Reason for application to the measurement family: This is needed to avoid filling in the direction in the abstract/figure captions with percentages/bias magnitudes from full-text tables. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality assessments, or clinical certification.

N24 · What are the exact version, product and platforms of the Roche method document?

Required materials and conditions: Roche method document version, document/product identifiers, supported platforms and installation/revision data
Conditions for verification: Preserve 2024-10 V2.0, 08429324501V2.0, 08429324160 and the e411/e601/e602 scope exactly as recorded.
Requirement and applicability: Required
Application exceptions: The currently retained document version and the versions actually installed in all laboratories are different facts.
Why this condition is needed: This is needed to avoid using a specific version of the method document as evidence of identical performance for all historical Roche reagents.
Referenced methods: C05: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed / D03: Chamgap's internally designed diagnostic condition; formal diagnostic-method evidence not reviewed / D08: Chamgap's internally designed diagnostic-applicability condition; general reference to M04 principles for distinguishing reports/studies. Reason for application to the measurement family: This is needed to avoid using a specific version of the method document as evidence of identical performance for all historical Roche reagents. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality assessments, or clinical certification.

N25 · What do the document's biotin test range and allowable deviations mean?

Required materials and conditions: The method document's test concentrations, allowable deviations, validation conditions and revision/installation information
Conditions for verification: Record ≤1200 ng/mL, an allowable deviation at TSH ≤0.2 µIU/mL of ≤0.02 µIU/mL, and ≤10% at higher TSH within the document's scope.
Requirement and applicability: Required
Application exceptions: Do not make new conversions between document concentrations and intake amounts. Allowable deviations differ from the absolute absence of interference.
Why this condition is needed: This is needed to avoid turning an analytical validation concentration into an oral safe dose or a guarantee of bias of 0.
Referenced methods: C06: M03 §3.2.4, M15 §15.3.1–15.3.3; outcome adaptations for each question are internally designed / D03: Chamgap's internally designed diagnostic condition; formal diagnostic-method evidence not reviewed / E05: M15 §15.3.1–15.3.3; internal application / H09: Chamgap's internally designed interpretation boundary. References M19 principles; not implementation of a formal causality tool. Reason for application to the measurement family: This is needed to avoid turning an analytical validation concentration into an oral safe dose or a guarantee of bias of 0. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality assessments, or clinical certification.

N26 · Was Li's published unit correction applied to the original units?

Required materials and conditions: Identity and original wording of the published correction, units before/after correction and locations where it applies
Conditions for verification: Under the 2017-11-21 correction, distinguish biotin in pg/mL from TSH in mIU/L, which was unchanged.
Requirement and applicability: Required
Application exceptions: Preserve the correction's original bibliographic information, including PMID/DOI. This is not a new external correction check or numerical conversion in this review.
Why this condition is needed: This is needed to avoid repeating the serum-biotin unit error in citations or also changing TSH units.
Referenced methods: C08: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is internally designed / C09: M04 §4.5, §4.6.3; limitations on the current data transformation follow the user's scope and internal design / C06: M03 §3.2.4, M15 §15.3.1–15.3.3; outcome adaptations for each question are internally designed. Reason for application to the measurement family: This is needed to avoid repeating the serum-biotin unit error in citations or also changing TSH units. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality assessments, or clinical certification.

N27 · Is day 7 biotin of 3601 an actual precisely measured concentration?

Required materials and conditions: Serum-biotin measurement range, handling of values above the upper limit and the actual analytical assignment rule
Conditions for verification: Preserve the original statement that all day 7 measurements exceeded 3600 and were assigned 3601.
Requirement and applicability: Required
Application exceptions: Do not convert 3601 and 3600 to other units or calculate new concentration/bias functions.
Why this condition is needed: This is needed to avoid using an assigned analysis value above the upper detection limit as an exact serum concentration or dose-concentration relationship.
Referenced methods: C06: M03 §3.2.4, M15 §15.3.1–15.3.3; outcome adaptations for each question are internally designed / E05: M15 §15.3.1–15.3.3; internal application / C07: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed. Reason for application to the measurement family: This is needed to avoid using an assigned analysis value above the upper detection limit as an exact serum concentration or dose-concentration relationship. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality assessments, or clinical certification.

N28 · Are results for other thyroid analytes/nonhormone analytes applied to this TSH question?

Required materials and conditions: Analyte-specific result tables within the paper/instrument and the original selected-endpoint boundary
Conditions for verification: Limit the currently selected outcome to TSH and leave extensions to other analytes/treatment/patient outcomes as separate questions.
Requirement and applicability: Boundaries for extensions
Application exceptions: Do not delete other results or judge them invalid. This exception means they are outside the scope of this standalone table.
Why this condition is needed: This is needed to avoid combining interference in other analytes from the same paper or instrument into TSH bias.
Referenced methods: C01: question-clarification principles in M03 §3.1, §3.2.1–3.2.4; detailed separation rules are internally designed / C06: M03 §3.2.4, M15 §15.3.1–15.3.3; outcome adaptations for each question are internally designed / E09: M03 §3.2.4; internally designed boundary for extensions / D09: Chamgap's internally designed boundary for diagnostic extensions; formal diagnostic-method evidence not reviewed. Reason for application to the measurement family: This is needed to avoid combining interference in other analytes from the same paper or instrument into TSH bias. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality assessments, or clinical certification.

N29 · Can measurements/analyses and missingness be linked by platform and time point?

Required materials and conditions: Participant→blood draw→specimen→platform measurement→analysis flow and handling of indeterminate/excluded/missing results
Conditions for verification: Separate currently known participants/specimens from the unverified platform-specific analysis flow.
Requirement and applicability: Required
Application exceptions: Do not present the absence of a detailed flow as 0 missing results or no exclusions.
Why this condition is needed: This is needed to avoid substituting enrollment/participant counts or time-point specimen counts as the actual denominator for every analysis.
Referenced methods: C07: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed / D06: Chamgap's internally designed diagnostic condition; formal diagnostic-method evidence not reviewed / H06: M19 §19.1.2–19.2.4, M04 §4.6.3; internal application. Reason for application to the measurement family: This is needed to avoid substituting enrollment/participant counts or time-point specimen counts as the actual denominator for every analysis. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality assessments, or clinical certification.

N30 · To what level were measurement procedures, calibration/QC and specimen handling verified?

Required materials and conditions: Assay-specific calibration/QC, specimen collection/storage, measurement order, reading/blinding and original methodological procedures
Conditions for verification: Distinguish the original verification locations from the information currently embedded, leaving gaps in comparison of calibration/QC, storage and measurement order/reading.
Requirement and applicability: Required
Application exceptions: This is limited to the absence of detailed procedural values in the KO/structure currently read. It does not mean that the entire original full text failed to report procedures.
Why this condition is needed: This is needed to avoid claiming that all analytical procedures and alternative explanations were verified solely from platform names and full-text reading labels.
Referenced methods: D03: Chamgap's internally designed diagnostic condition; formal diagnostic-method evidence not reviewed / D05: Chamgap's internally designed diagnostic condition; formal diagnostic-method evidence not reviewed / E03: M08 Table 8.2.a, M03 §3.2.4; internal application. Reason for application to the measurement family: This is needed to avoid claiming that all analytical procedures and alternative explanations were verified solely from platform names and full-text reading labels. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality assessments, or clinical certification.

N31 · Were registration, protocol and SAP compared with actual platforms/time points/contrasts?

Required materials and conditions: NCT03034707 and ChiCTR1800020472 histories, protocol/SAP, plans for platforms/endpoints/time points and numerical supplements
Conditions for verification: Link registration identifiers to original analysis locations and record that plans/multiplicity and the full numerical supplements have not been compared.
Requirement and applicability: Required
Application exceptions: Do not convert unverified registration/planning into confirmed nonregistration or selective reporting.
Why this condition is needed: This is needed to avoid arbitrarily establishing that favorable reported platforms/time points match the original advance plan.
Referenced methods: E04: M08 §8.2.2, M15 §15.3.1; internal application / E06: M08 Table 8.2.a, M04 §4.6.3; internal application / C09: M04 §4.5, §4.6.3; limitations on the current data transformation follow the user's scope and internal design / D05: Chamgap's internally designed diagnostic condition; formal diagnostic-method evidence not reviewed. Reason for application to the measurement family: This is needed to avoid arbitrarily establishing that favorable reported platforms/time points match the original advance plan. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality assessments, or clinical certification.

N32 · Were reports, platforms, corrections and method documents counted as independent human replications?

Required materials and conditions: Report-family-assay/outcome relationships and links to registrations, corrections, method documents and repeat citations
Conditions for verification: Link the identities and roles of F01's S01/S02/S03, F02's S04, F03's S05 and A01's S08.
Requirement and applicability: Required
Application exceptions: The direct data from F01/F02 and the abstract-level corroboration from F03 differ in evidence level. A01 is not a human study.
Why this condition is needed: This is needed to avoid adding together the main article/supplement/correction from the same study, multiple platforms using the same specimens, and manufacturer documents as independent human replications.
Referenced methods: C02: Distinction between studies and reports in M04 §4.6.1–4.6.2; linking cohorts/outcomes is an internal application / E07: M04 §4.6.1–4.6.2, M15 §15.3.1; internal application / H07: M04 §4.6.1–4.6.2; adaptation for harm data is internally designed / D08: Chamgap's own diagnostic-application condition; general reference to M04's principle of distinguishing reports from studies. Reason for application to the measurement family: This is needed to avoid adding together the main article/supplement/correction from the same study, multiple platforms using the same specimens, and manufacturer documents as independent human replications. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality methods, or clinical certification.

N33 · To which report do funding, product provision and author relationships belong?

Required materials and conditions: Study-specific funding, product roles, author relationships, declarations in manufacturer performance documents, and their original locations
Conditions for verification: Retain Li's support/relationships, Zhang's declaration of none, Ylli's unverified details and the Roche manufacturer document separately.
Requirement and applicability: Required
Application exceptions: Support or competing interests do not automatically invalidate a result, and a declaration of none does not establish independent verification.
Why this condition is needed: This is needed to avoid treating manufacturer documents or unverified funding as independent performance validation.
Referenced methods: C10: Chamgap's own independence and attribution condition. The official methods sections used in this demonstration do not warrant all of these detailed items / C02: Distinction between studies and reports in M04 §4.6.1–4.6.2; linking cohorts/outcomes is an internal application. Reason for application to the measurement family: This is needed to avoid treating manufacturer documents or unverified funding as independent performance validation. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality methods, or clinical certification.

N34 · Has current reading of local summaries been distinguished from historical external access and access dates?

Required materials and conditions: Physical material types, URLs, historical access_level/location, report-specific access-date records and actions in this review
Conditions for verification: Separate current reading of the retained KO/structure and bibliography from unattempted access, non-acquisition and non-reading for each external material type, and from historical access levels.
Requirement and applicability: Required
Application exceptions: The original verified_date is a global review date. If a report-specific access date is absent, it remains null; historical access failures are not displayed as current failures.
Why this condition is needed: This is needed to avoid elevating publisher_full_text or other historical access_level values, or links, to original-source reading in this review.
Referenced methods: C03: Data collection/selection principles in M04 §4.5–4.6; separation of access from reading and the hyperlink contract are internally designed / C09: M04 §4.5, §4.6.3; limits on the current data transition follow the user-defined scope and internal design. Reason for application to the measurement family: This is needed to avoid elevating publisher_full_text or other historical access_level values, or links, to original-source reading in this review. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality methods, or clinical certification.

N35 · Were discovery leads for S10/S11/S12 elevated to direct performance figures?

Required materials and conditions: Original full texts/concentration-response tables and identity/access records for the S10 guideline, S11 LOCI and S12 clinical-measurement candidates
Conditions for verification: Retain the actual identities of the three candidates, the scope of historical discovery/failure, and the unverified original tables.
Requirement and applicability: Required
Application exceptions: Separate unattempted access in the current review from historical full-text access failures. A link/PMCID is not evidence that the full text was read.
Why this condition is needed: This is needed to avoid inventing original quantitative tables from the titles of guideline, LOCI and routine immunoassay papers whose full texts were not accessed.
Referenced methods: C03: Data collection/selection principles in M04 §4.5–4.6; separation of access from reading and the hyperlink contract are internally designed / C09: M04 §4.5, §4.6.3; limits on the current data transition follow the user-defined scope and internal design / C08: M04 §4.6.3, M15 §15.3.1–15.3.3; status separation is internally designed. Reason for application to the measurement family: This is needed to avoid inventing original quantitative tables from the titles of guideline, LOCI and routine immunoassay papers whose full texts were not accessed. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality methods, or clinical certification.

N36 · Were the historical NIH/FDA extracts counted as independent TSH studies?

Required materials and conditions: Historical NIH/FDA extracts, original access histories, and the documents' actual scope of analytes/secondary citations
Conditions for verification: Retain S06/S07's inherited_official_extract status, general safety role and boundary of no new search.
Requirement and applicability: Required
Application exceptions: Do not transfer the analyte scope of the FDA troponin document to direct TSH figures.
Why this condition is needed: This is needed to avoid double-counting official general safety documents and secondary citations as independent human measurement results.
Referenced methods: C02: Distinction between studies and reports in M04 §4.6.1–4.6.2; linking cohorts/outcomes is an internal application / C03: Data collection/selection principles in M04 §4.5–4.6; separation of access from reading and the hyperlink contract are internally designed / H09: Chamgap's own interpretation boundary. Reference to M19 principles, not implementation of a formal causality tool. Reason for application to the measurement family: This is needed to avoid double-counting official general safety documents and secondary citations as independent human measurement results. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality methods, or clinical certification.

N37 · Is AACC guidance distinguished from individual stopping intervals and testing/treatment schedules?

Required materials and conditions: The actual context of guidance recommendations by population, renal function/exposure and assay, and individual testing conditions
Conditions for verification: Link AACC's historical scope to the prohibition on a universal stopping interval or individual treatment changes.
Requirement and applicability: Required
Application exceptions: The original numerical recommendations in the guidance are not embedded in the current JSON, so no new values are presented.
Why this condition is needed: This is needed to avoid converting general guidance or study time points into a safe stopping interval for a particular person.
Referenced methods: D09: Chamgap's own boundary for diagnostic extensions; official diagnostic-method evidence not reviewed / E08: M03 §3.2.1–3.2.4; dose, duration and effect-modification details are internally designed / H02: Design-specific harm questions in M19 §19.2; timing-relationship details are internally designed / H08: M19 §19.1.2–19.2.4; internal application. Reason for application to the measurement family: This is needed to avoid converting general guidance or study time points into a safe stopping interval for a particular person. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality methods, or clinical certification.

N38 · What possibility and what actual observations does the Warning represent?

Required materials and conditions: Reference-limit crossing of measured values, actual clinical judgments/actions after testing, and harm definitions/collection/denominators/follow-up
Conditions for verification: Retain the original safety Warning, measured values and reference-limit crossing, while distinguishing the absence of data on actual misdiagnosis/harm.
Requirement and applicability: Required
Application exceptions: Do not reuse the presence of measurement bias as a judgment of individual safety/efficacy.
Why this condition is needed: This is needed to avoid converting the possibility of interpretation errors from falsely low measurements into an actual patient harm rate or established causation of an event.
Referenced methods: H01: M19 §19.1.2–19.2.4; detailed distinctions are internally designed / H04: M19 §19.1.2–19.2.4; internal application / H09: Chamgap's own interpretation boundary. Reference to M19 principles, not implementation of a formal causality tool / D09: Chamgap's own boundary for diagnostic extensions; official diagnostic-method evidence not reviewed. Reason for application to the measurement family: This is needed to avoid converting the possibility of interpretation errors from falsely low measurements into an actual patient harm rate or established causation of an event. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality methods, or clinical certification.

N39 · Have bias magnitude and duration outside the healthy-adult conditions been verified?

Required materials and conditions: Actual exposure, reagents and blood-draw-time-specific bias/duration information for populations defined by renal function, pregnancy, childhood or high-dose treatment
Conditions for verification: Record the direct study conditions separately from unverified information on special populations and long-term/rare situations.
Requirement and applicability: Required for extension claims; supplementary to the narrow question
Application exceptions: Studies in every vulnerable population are not mandatory to establish this narrow measurement question, but direct information is required for the corresponding extension claims.
Why this condition is needed: This is needed to avoid extending the results of short-term exposure in healthy adults to all populations with renal impairment, pregnancy, childhood or high-dose treatment.
Referenced methods: C04: M03 §3.2.1; detailed population conditions are internally designed / H08: M19 §19.1.2–19.2.4; internal application / E08: M03 §3.2.1–3.2.4; dose, duration and effect-modification details are internally designed. Reason for application to the measurement family: This is needed to avoid extending the results of short-term exposure in healthy adults to all populations with renal impairment, pregnancy, childhood or high-dose treatment. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality methods, or clinical certification.

N40 · Which retained reference date underlies the statements, and what changes trigger a new review?

Required materials and conditions: Reference date, current review date, search/access records, reagent revisions, original corrections/retractions, and new numerical/classification data
Conditions for verification: Link the evidence-review date of 2026-09-15 and this review date to unverified information, corrections/revisions and the update scope.
Requirement and applicability: Required
Application exceptions: Verification of new reagent documents, corrections, retractions and numerical/classification errors is not a request for automatic execution now.
Why this condition is needed: This is needed to avoid overstating the retained current value as verification of all the latest literature or current installations, or as an exhaustive search.
Referenced methods: C09: M04 §4.5, §4.6.3; limits on the current data transition follow the user-defined scope and internal design / C08: M04 §4.6.3, M15 §15.3.1–15.3.3; status separation is internally designed / C03: Data collection/selection principles in M04 §4.5–4.6; separation of access from reading and the hyperlink contract are internally designed. Reason for application to the measurement family: This is needed to avoid overstating the retained current value as verification of all the latest literature or current installations, or as an exhaustive search. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality methods, or clinical certification.

Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle: Clearly record the question, eligibility criteria and reasons for changes, and distinguish variations in the intervention.
Extent of review: This is a comparison of actual copies/SHA for case 1585's 5 original methodology HTML files, retaining their original bytes, and historical reuse of the principles from that time. It is not new reading of full methods texts, implementation of formal assessment tools or clinical certification.

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle: Distinguish and link studies and reports, and do not omit a study solely because its outcomes are not reported.
Extent of review: This is a comparison of actual copies/SHA for case 1585's 5 original methodology HTML files, retaining their original bytes, and historical reuse of the principles from that time. It is not new reading of full methods texts, implementation of formal assessment tools or clinical certification.

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle: Hold the outcome and effect of interest fixed, then assess randomization, deviations, missing data, measurement and selective reporting.
Extent of review: This is a comparison of actual copies/SHA for case 1585's 5 original methodology HTML files, retaining their original bytes, and historical reuse of the principles from that time. It is not new reading of full methods texts, implementation of formal assessment tools or clinical certification.

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle: Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.
Extent of review: This is a comparison of actual copies/SHA for case 1585's 5 original methodology HTML files, retaining their original bytes, and historical reuse of the principles from that time. It is not new reading of full methods texts, implementation of formal assessment tools or clinical certification.

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle: Questions about harms may require designs, populations and follow-up different from efficacy questions. Case reports do not establish incidence.
Extent of review: This is a comparison of actual copies/SHA for case 1585's 5 original methodology HTML files, retaining their original bytes, and historical reuse of the principles from that time. It is not new reading of full methods texts, implementation of formal assessment tools or clinical certification.

What the statuses mean

Met: The record meets the specified narrow conditions for measurement identity, attribution/units, version/reading and display. This does not establish efficacy, absence of interference or individual safety, or verify that the external full text has been checked in the current review.
Partly verified: Relevant retained observations exist, but some necessary methods, reagents/versions, denominators, quantitative intervals or comparisons against original sources remain unverified.
Unverified: The value could not be established from the currently retained materials and the scope verified at that time. This does not mean bias 0, normality, absence/failure of data or absence of interference.
Not reported: Used only within the scope of non-reporting in sections actually read or in the historical summaries currently specified. It is not extended to entire external full texts that remain unread in this review.
Conflicting information: Specify retained discrepancies or possible errors concerning the same fact in each row. Different platforms, time points or formal contrasts/simple differences do not in themselves constitute a conflict.
Inaccessible: Used only for an actual access failure in this review. No external access was attempted in this review, so historical failures are not carried over as current status.
Review incomplete: Limited to the scope in which comparison against current external materials has not been performed. It does not mean that the entire review of the retained JSON and model, which was actually completed, is incomplete.
Not applicable: Limited to other analytes outside the required outcomes of the narrow TSH question. This is not a substitute for unread/unverified status, or certification of no interference or safety.

Change history

2026-11-03 · Public page/material version 1.0

The 40 review items for the existing measurement question have been transferred to the public-facing display and data. Original verification statuses, figures, units, versions and unverified information are retained, without a new clinical search, scoring or reassessment.

The stored-material review date (2026-10-05) and original evidence cut-off (2026-09-15) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · Does this table address a measurement question and prevent the application of efficacy grades and scores?

Current findings: The original data have measurement_only=true, question_type=measurement. Efficacy grade·score·axes are not_applicable, and efficacy badges, aggregate ratings and a universal stopping interval are prohibited. The original grade ?·score null are not used as a new efficacy assessment.
Verification status: Met
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: This documentation condition links the original measurement classification and display prohibitions unchanged. It does not mean certification of clinical efficacy or absence of interference.
Reason for missing information: No new efficacy grade or aggregate measurement score is created.
Required materials and conditions: Measurement-only classification, fields marking efficacy as not applicable, and a display contract prohibiting efficacy badges/aggregate ratings/a universal stopping interval
Materials to obtain first: Measurement-only classification, fields marking efficacy as not applicable, and a display contract prohibiting efficacy badges/aggregate ratings/a universal stopping interval
Further research: Cross-check the display paths for measurements, reagent performance, document quality and patient outcomes separately to prevent conflated labeling.
Remaining uncertainty: No new efficacy grade or aggregate measurement score is created. This status reflects the documented scope of the specific narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/personal safety, the actual misdiagnosis rate, or absence of evidence worldwide.
Conditions for verification: Preserve measurement_only, the measurement type, the non-applicability of efficacy grade/score/axes, and the original display_contract unchanged.
Why this condition is needed: This is needed to prevent falsely low measurements from being recast as treatment effects or an aggregate grade.
Application exceptions: The original grade ?·score null and document quality B are historical values. Blue in the condition status indicates verification of a narrow documentation condition, not an efficacy badge.
Referenced methods: C01: Question clarification principles in M03 §3.1, §3.2.1–3.2.4; the detailed separation rules are internally designed / C09: M04 §4.5, §4.6.3; limits on the current data transformation follow the user-defined scope and are internally designed / D01: Chamgap's own diagnostic condition; M03 question/population principles serve only as general references. Reason for application to the measurement family: This is needed to prevent falsely low measurements from being recast as treatment effects or an aggregate grade. This is not a formal implementation of diagnostic/QUADAS/STARD·RoB/GRADE/causality methods or clinical certification.

Related sources

N02 · Which exposure, specimen, comparison and measurement outcome are brought together in one table?

Current findings: The single claim concerns falsely low readings in specific serum TSH assays after oral biotin. The actual comparisons are within the same people before exposure and after washout, or between platforms using specimens from the same time point; they do not concern biotin's thyroid treatment effect or actual misdiagnosis rates.
Verification status: Met
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: The original claim and the boundaries of the measurement family were verified. Results from some assays were not extended to all TSH assays or clinical diseases.
Reason for missing information: Other analytes, actual changes in thyroid function, misdiagnosis/patient harm and a universal stopping interval are separate questions.
Required materials and conditions: The original claim and a fixed question specified by healthy adults, oral exposure, serum TSH, platform/reagent, dose and blood sampling time
Materials to obtain first: The original claim and a fixed question specified by healthy adults, oral exposure, serum TSH, platform/reagent, dose and blood sampling time
Further research: Construct a matrix of platform, reagent, exposure and time point, and cross-check measurement bias separately from physiological changes/clinical outcomes.
Remaining uncertainty: Other analytes, actual changes in thyroid function, misdiagnosis/patient harm and a universal stopping interval are separate questions. This status reflects the documented scope of the specific narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/personal safety, the actual misdiagnosis rate, or absence of evidence worldwide.
Conditions for verification: Fix the oral exposure, serum TSH, assay-specific falsely low readings and actual within-person/same-specimen comparisons, and distinguish questions that extend beyond them.
Why this condition is needed: This is needed to avoid conflating thyroid disease, other analytes and all test interference with this TSH measurement bias.
Application exceptions: Even when some concepts from the diagnostic accuracy family are used as references, the question is not changed into one about sensitivity/specificity or a clinical treatment trial.
Referenced methods: C01: Question clarification principles in M03 §3.1, §3.2.1–3.2.4; the detailed separation rules are internally designed / C04: M03 §3.2.1; detailed population conditions are internally designed / C05: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed / C06: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed / D01: Chamgap's own diagnostic condition; M03 question/population principles serve only as general references / D09: Chamgap's own boundary for diagnostic extensions; formal diagnostic methodology evidence has not been reviewed / E09: M03 §3.2.4; internally designed boundary for extensions. Reason for application to the measurement family: This is needed to avoid conflating thyroid disease, other analytes and all test interference with this TSH measurement bias. This is not a formal implementation of diagnostic/QUADAS/STARD·RoB/GRADE/causality methods or clinical certification.

Related sources S01 S04 S05 S08

N03 · Which TSH measure in which specimen does the observed outcome represent?

Current findings: The selected outcome is the serum TSH assay value. Li's TSH is in mIU/L and the Roche document's criteria are in µIU/mL; these are distinguished from blood biotin in pg/mL and document values in ng/mL. The original units were not converted and combined.
Verification status: Met
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: The condition distinguishing the retained original units and analytes was verified. Physiological thyroid status was not determined.
Reason for missing information: Conversions between original documents or application of patient diagnostic thresholds are not performed in this review.
Required materials and conditions: Serum TSH analyte, units, time-point/contrast definitions, and separate blood biotin units
Materials to obtain first: Serum TSH analyte, units, time-point/contrast definitions, and separate blood biotin units
Further research: Cross-check analytes, units and measures against each original table/document without generating new converted values or clinical status classifications.
Remaining uncertainty: Conversions between original documents or application of patient diagnostic thresholds are not performed in this review. This status reflects the documented scope of the specific narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/personal safety, the actual misdiagnosis rate, or absence of evidence worldwide.
Conditions for verification: Assign assay-specific serum TSH time-point means, formal contrasts and reference-limit crossings to their respective original units/time points.
Why this condition is needed: This is needed to avoid substituting blood biotin concentrations, TSH measurements or disease status for one another.
Application exceptions: Keep blood biotin in pg/mL and reagent-document values in ng/mL, and TSH in mIU/L and document values in µIU/mL, each in its original units. No new conversions are performed.
Referenced methods: C06: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed / D03: Chamgap's own diagnostic condition; formal diagnostic methodology evidence has not been reviewed. Reason for application to the measurement family: This is needed to avoid substituting blood biotin concentrations, TSH measurements or disease status for one another. This is not a formal implementation of diagnostic/QUADAS/STARD·RoB/GRADE/causality methods or clinical certification.

Related sources S01 S03 S08

N04 · Are the actual form, batch and total exposure to the biotin supplement known?

Current findings: Oral biotin supplement exposure is retained in the record, but the manufacturing source, exact chemical form, tablet/capsule, composition, batch, purity and total dietary exposure remain unverified.
Verification status: Unverified
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: The currently retained information does not identify product details or total actual exposure. The nominal dose was not used to fill these gaps.
Reason for missing information: Product specifications, adherence/intake records and dietary exposure for each trial.
Required materials and conditions: Exact chemical form, formulation, batch, purity and dosing records for the study product, and total dietary exposure data
Materials to obtain first: Exact chemical form, formulation, batch, purity and dosing records for the study product, and total dietary exposure data
Further research: Link study product specifications and actual intake records to measurements by platform/time point to compare differences between products.
Remaining uncertainty: Product specifications, adherence/intake records and dietary exposure for each trial. This status reflects the documented scope of the specific narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/personal safety, the actual misdiagnosis rate, or absence of evidence worldwide.
Conditions for verification: Distinguish each study's supplement exposure from unverified product/dietary details.
Why this condition is needed: This is needed to avoid extending the name biotin and the nominal dose to the composition, purity and actual intake of all supplements.
Application exceptions: Unverified manufacturing source, chemical form, tablet/capsule, batch and dietary exposure do not constitute a finding that a particular product is defective.
Referenced methods: C05: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed / H05: Design considerations in M19 §19.2.2–19.2.4; detailed confounding records are internally designed. Reason for application to the measurement family: This is needed to avoid extending the name biotin and the nominal dose to the composition, purity and actual intake of all supplements. This is not a formal implementation of diagnostic/QUADAS/STARD·RoB/GRADE/causality methods or clinical certification.

Related sources S01 S04 S05

N05 · Were dosing duration and the interval from the last dose to blood sampling distinguished?

Current findings: Li used 10 mg/day for 7 days, with sampling approximately 2 hours after the last dose on day 7, and after 7 days off on day 14. Zhang used the same 10 participants at 5/10 mg/day for 7 days each; Ylli used 10 mg/day for 8 days, with measurements on day 1/day 8 before dosing and at 2 hours and 5 hours.
Verification status: Partly verified
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: The reported timelines were linked, but not all records of individual actual intake/timing and total dietary exposure were verified.
Reason for missing information: Actual individual dosing times, adherence, total exposure and original blood sampling records for each trial.
Required materials and conditions: Nominal oral dose, dosing start/end, actual last dose and blood sampling times for each trial
Materials to obtain first: Nominal oral dose, dosing start/end, actual last dose and blood sampling times for each trial
Further research: Cross-check dose, dosing duration, last dose and blood sampling time against the original records as separate axes.
Remaining uncertainty: Actual individual dosing times, adherence, total exposure and original blood sampling records for each trial. This status reflects the documented scope of the specific narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/personal safety, the actual misdiagnosis rate, or absence of evidence worldwide.
Conditions for verification: Retain the oral dose, dosing duration, assessment day and post-dose blood sampling time for Li, Zhang and Ylli separately by study.
Why this condition is needed: This is needed to avoid treating 7-day/8-day exposure and blood sampling after 2 hours/5 hours/8 hours as the same timeline.
Application exceptions: The tested 5/10 mg doses are not interpreted as safe doses, optimal doses or personal dosing/stopping instructions.
Referenced methods: C05: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed / C06: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed / H02: Design-specific harm questions in M19 §19.2; details of temporal relationships are internally designed / E08: M03 §3.2.1–3.2.4; details of dose, duration and effect modification are internally designed. Reason for application to the measurement family: This is needed to avoid treating 7-day/8-day exposure and blood sampling after 2 hours/5 hours/8 hours as the same timeline. This is not a formal implementation of diagnostic/QUADAS/STARD·RoB/GRADE/causality methods or clinical certification.

Related sources S01 S04 S05

N06 · To which populations can the measurements in healthy adults be applied?

Current findings: The detailed direct evidence from Li and Zhang concerns healthy adults. Ylli has an abstract-level record of 13 adults, while the detailed analysis population remains unverified. These data do not establish the magnitude/duration in patients, people with renal impairment, pregnant people, children or high-dose treatment groups.
Verification status: Partly verified
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: The scope of the reported population is available, but detailed recruitment/baseline characteristics and general applicability are currently unverified.
Reason for missing information: Selection, exclusion and baseline status for each population, and direct measurement information for each special population.
Required materials and conditions: Recruitment/selection, baseline thyroid/renal function, age/sex composition and special-population data for each trial
Materials to obtain first: Recruitment/selection, baseline thyroid/renal function, age/sex composition and special-population data for each trial
Further research: Cross-check population composition and baseline status against exposure/measurement conditions, and assess applicability to other populations using direct data from those populations.
Remaining uncertainty: Selection, exclusion and baseline status for each population, and direct measurement information for each special population. This status reflects the documented scope of the specific narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/personal safety, the actual misdiagnosis rate, or absence of evidence worldwide.
Conditions for verification: Distinguish each study's actually reported population from unverified selection/baseline characteristics and limitations concerning special populations.
Why this condition is needed: This is needed to avoid extending a small sample of healthy people to all patients, people with renal impairment, pregnant people, children and high-dose treatment groups.
Application exceptions: The description of participants as healthy adults alone does not verify recruitment representativeness, sex/age composition and exclusion criteria in full.
Referenced methods: C04: M03 §3.2.1; detailed population conditions are internally designed / D02: Chamgap's own diagnostic sampling condition; formal diagnostic methodology evidence has not been reviewed / H08: M19 §19.1.2–19.2.4; internal application. Reason for application to the measurement family: This is needed to avoid extending a small sample of healthy people to all patients, people with renal impairment, pregnant people, children and high-dose treatment groups. This is not a formal implementation of diagnostic/QUADAS/STARD·RoB/GRADE/causality methods or clinical certification.

Related sources S01 S04 S05

N07 · What denominators do Li's 6 people and 18 time-point specimens represent?

Current findings: Li compared 6 healthy adults before exposure, on day 7 and on day 14. The 18 serum time-point specimens were not treated as 18 participants or 18 independent samples.
Verification status: Met
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: The retained distinction between participant and repeated-specimen denominators was verified. This did not newly establish every detailed analysis denominator.
Reason for missing information: Detailed flow of analyzable specimens and exclusions/missingness by platform/time point.
Required materials and conditions: Li's participant count, time-point specimen count, and measurement/analysis and exclusion flow by platform
Materials to obtain first: Li's participant count, time-point specimen count, and measurement/analysis and exclusion flow by platform
Further research: Cross-check the correspondence among participants, specimens, platforms and time points against the original flow/tables to verify the unit of analysis.
Remaining uncertainty: Detailed flow of analyzable specimens and exclusions/missingness by platform/time point. This status reflects the documented scope of the specific narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/personal safety, the actual misdiagnosis rate, or absence of evidence worldwide.
Conditions for verification: Distinguish repeated measurements within the same 6 people from the 18 time-point specimens, and retain gaps in the actual analysis flow.
Why this condition is needed: This is needed to avoid overstating sample size and precision by counting repeated specimens as independent participants.
Application exceptions: Verification of 18 specimens does not mean that missingness and exclusion flows were verified for every assay/time point.
Referenced methods: C07: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed / D06: Chamgap's own diagnostic condition; formal diagnostic methodology evidence has not been reviewed. Reason for application to the measurement family: This is needed to avoid overstating sample size and precision by counting repeated specimens as independent participants. This is not a formal implementation of diagnostic/QUADAS/STARD·RoB/GRADE/causality methods or clinical certification.

Related sources S01

N08 · Do Zhang's two doses represent trials with different groups of 10 people each?

Current findings: In Zhang, the same 10 healthy adults used 5 mg/day and 10 mg/day for 7 days each. The exact numbers of analyzed specimens by platform and time point remain unverified.
Verification status: Partly verified
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: The boundary of the same 10 people is clear, but detailed analyzed-specimen denominators remain unresolved.
Reason for missing information: Exposure order/intervals and actual numbers of analyzed specimens for each dose, platform and time point.
Required materials and conditions: Identity of the same participants, exposure order and duration, and analysis flow by dose/platform/time point
Materials to obtain first: Identity of the same participants, exposure order and duration, and analysis flow by dose/platform/time point
Further research: Cross-check exposure order, washout intervals and period effects within the same people to verify the dependence of repeated measurements.
Remaining uncertainty: Exposure order/intervals and actual numbers of analyzed specimens for each dose, platform and time point. This status reflects the documented scope of the specific narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/personal safety, the actual misdiagnosis rate, or absence of evidence worldwide.
Conditions for verification: Retain the same 10 people, the fixed sequence of 7 days each, and the unverified numbers of analyzed specimens by platform/time point.
Why this condition is needed: This is needed to avoid counting fixed-sequence exposures in the same participants as 20 people or two independent trials.
Application exceptions: The results at the two doses are not recast as a randomized dose comparison or an estimate of interaction between doses.
Referenced methods: C02: Distinction between studies and reports in M04 §4.6.1–4.6.2; cohort/outcome linkage is an internal application / C07: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed / D06: Chamgap's own diagnostic condition; formal diagnostic methodology evidence has not been reviewed. Reason for application to the measurement family: This is needed to avoid counting fixed-sequence exposures in the same participants as 20 people or two independent trials. This is not a formal implementation of diagnostic/QUADAS/STARD·RoB/GRADE/causality methods or clinical certification.

Related sources S04

N09 · Do Ylli's 13 people constitute the analysis denominator for every TSH value?

Current findings: Ylli is recorded as having enrolled 13 adults. Extraction is limited to the abstract and figure captions; detailed TSH analysis denominators and quantitative full-text tables remain unverified.
Verification status: Partly verified
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: The enrollment count and level of material were retained, and the actual analysis n was not arbitrarily fixed at 13.
Reason for missing information: Completion and analysis counts and quantitative tables by time point/assay.
Required materials and conditions: Ylli's enrollment/completion/TSH analysis denominators, and specimen flow for each original quantitative table and figure
Materials to obtain first: Ylli's enrollment/completion/TSH analysis denominators, and specimen flow for each original quantitative table and figure
Further research: Map enrollment counts and analysis populations/time points to the original tables to verify the scope of missingness and exclusions.
Remaining uncertainty: Completion and analysis counts and quantitative tables by time point/assay. This status reflects the documented scope of the specific narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/personal safety, the actual misdiagnosis rate, or absence of evidence worldwide.
Conditions for verification: Distinguish the enrollment of 13 adults and the scope of the abstract/figure captions from the unverified detailed TSH analysis denominators.
Why this condition is needed: This is needed to avoid automatically inserting the enrollment count in the abstract as the analysis denominator for full-text tables.
Application exceptions: Retain the direction reported in the figure captions and abstract, without reconstructing quantitative full-text tables that could not be accessed.
Referenced methods: C07: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed / D06: Chamgap's own diagnostic condition; formal diagnostic methodology evidence has not been reviewed / C03: Data collection/selection principles in M04 §4.5–4.6; the separation of access and reading and the hyperlink contract are internally designed. Reason for application to the measurement family: This is needed to avoid automatically inserting the enrollment count in the abstract as the analysis denominator for full-text tables. This is not a formal implementation of diagnostic/QUADAS/STARD·RoB/GRADE/causality methods or clinical certification.

Related sources S05

N10 · What comparisons does the actual design provide, and what does it fail to control?

Current findings: Li is a nonrandomized comparison within the same people before exposure, after exposure and after washout, and between platforms using the same specimens. Zhang uses a fixed sequence, and Ylli uses prospective within-person exposure comparisons. These were not treated as treatment effects between randomized placebo groups.
Verification status: Partly verified
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: The actual design descriptions are verified, but detailed controls for order, concurrent changes and blinding remain unverified.
Reason for missing information: Specific original records of order, background/concurrent changes and reading/measurement procedures.
Required materials and conditions: Actual exposure order, concurrent changes, control of background factors, and measurement/reading conditions
Materials to obtain first: Actual exposure order, concurrent changes, control of background factors, and measurement/reading conditions
Further research: Distinguish comparisons across time points within the same people from comparisons of concurrent specimens to assess the effects of order, time and background changes.
Remaining uncertainty: Specific original records of order, background/concurrent changes and reading/measurement procedures. This status reflects the documented scope of the specific narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/personal safety, the actual misdiagnosis rate, or absence of evidence worldwide.
Conditions for verification: Retain Li's nonrandomized repeated measurements, Zhang's fixed sequence and Ylli's prospective within-person comparison, along with limitations concerning time/concurrent changes.
Why this condition is needed: This is needed to avoid presenting within-person exposure comparisons as randomized placebo efficacy trials.
Application exceptions: Direct measurement results are not removed merely because the design is nonrandomized. The existence of a clinical RCT is not an essential prerequisite for measurement bias.
Referenced methods: E01: M08 §8.1–8.2.3; internal application / E04: M08 §8.2.2, M15 §15.3.1; internal application / D05: Chamgap's own diagnostic condition; formal diagnostic methodology evidence has not been reviewed / H05: Design considerations in M19 §19.2.2–19.2.4; detailed confounding records are internally designed. Reason for application to the measurement family: This is needed to avoid presenting within-person exposure comparisons as randomized placebo efficacy trials. This is not a formal implementation of diagnostic/QUADAS/STARD·RoB/GRADE/causality methods or clinical certification.

Related sources S01 S04 S05

N11 · What comparison references do pre-exposure/post-washout measurements and other platforms provide?

Current findings: The actual comparisons involve the same people before exposure and after washout, and platforms using specimens from the same time point. Comparisons with biotin-independent methods are relevant to verifying measurement interference, but are not diagnostic tests that establish a patient's thyroid status.
Verification status: Partly verified
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: The content of the comparisons is linked; independent reference methods/true values and diagnostic accuracy have not been verified in these materials.
Reason for missing information: Separate information on calibration/traceability of comparator methods, independent reference methods and physiological true values.
Required materials and conditions: Definitions of time contrasts, and analytical principles and traceability/reference-method information for comparisons using the same specimens
Materials to obtain first: Definitions of time contrasts, and analytical principles and traceability/reference-method information for comparisons using the same specimens
Further research: Cross-check paired time contrasts and assay differences in specimens from the same time point separately, and distinguish them from determining a clinical true value.
Remaining uncertainty: Separate information on calibration/traceability of comparator methods, independent reference methods and physiological true values. This status reflects the documented scope of the specific narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/personal safety, the actual misdiagnosis rate, or absence of evidence worldwide.
Conditions for verification: Link within-person time contrasts and comparator platforms using specimens from the same time point separately, and explain the limitations of the reference methods.
Why this condition is needed: This is needed to avoid confusing differences between assays with established diagnostic criteria for patients' thyroid conditions.
Application exceptions: Even a biotin-independent method does not automatically establish an independent physiological TSH true value or a gold standard for clinical disease.
Referenced methods: C05: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed / C06: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed / D04: Chamgap's own diagnostic condition; formal diagnostic methodology evidence has not been reviewed / E04: M08 §8.2.2, M15 §15.3.1; internal application. Reason for application to the measurement family: This is needed to avoid confusing differences between assays with established diagnostic criteria for patients' thyroid conditions. This is not a formal implementation of diagnostic/QUADAS/STARD·RoB/GRADE/causality methods or clinical certification.

Related sources S01 S02 S04

N12 · Were the principles and instrument identities of the TSH assays distinguished?

Current findings: Distinguish Roche cobas e602, Ortho VITROS 5600, Siemens Dimension Vista 1500, Abbott ARCHITECT 2000 and Zhang's Beckman UniCel DxI 800. Also retain Vista's biotin dependence and the biotin independence of Zhang's Beckman/Abbott TSH assays with their respective results.
Verification status: Partly verified
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: Differences in retained instrument identities and principles are available, but historical lots and actual reagent installations in individual laboratories have not been fully verified.
Reason for missing information: Original procedures, reagent lots/versions and installation records for each assay.
Required materials and conditions: Instruments, reagents, principles, specimen procedures and interference tolerance thresholds for each analyte
Materials to obtain first: Instruments, reagents, principles, specimen procedures and interference tolerance thresholds for each analyte
Further research: Cross-check not only instrument names but also the TSH reagents' capture/detection methods against the results at the exposure tested.
Remaining uncertainty: Original procedures, reagent lots/versions and installation records for each assay. This status reflects the documented scope of the specific narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/personal safety, the actual misdiagnosis rate, or absence of evidence worldwide.
Conditions for verification: Link the TSH results from Roche, Ortho, Siemens, Abbott and Beckman separately to the level of verification of their principles/versions.
Why this condition is needed: This is needed to avoid treating interference on all instruments as identical solely because methods are described as sandwich or biotin-dependent.
Application exceptions: Vista uses a biotin-dependent TSH assay, yet there was no significant difference at the exposure tested. A positive finding is not assigned on the basis of the principle alone.
Referenced methods: C05: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed / C06: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed / D03: Chamgap's own diagnostic condition; formal diagnostic methodology evidence has not been reviewed / E03: M08 Table 8.2.a, M03 §3.2.4; internal application. Reason for application to the measurement family: This is needed to avoid treating interference on all instruments as identical solely because methods are described as sandwich or biotin-dependent. This is not a formal implementation of diagnostic/QUADAS/STARD·RoB/GRADE/causality methods or clinical certification.

Related sources S01 S02 S04

N13 · Are historical tests and current reagents with the same instrument name being treated as identical?

Current findings: Historical reagent lots and interference tolerance thresholds remain unverified. Roche's 2024-10 V2.0 document provides a known version boundary, but does not verify reagent identity at the time of the trials or currently across all laboratories.
Verification status: Unverified
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: The required identity of lots/installations cannot be established from instrument names alone.
Reason for missing information: Direct information on historical/current reagent lots, versions and laboratory installations.
Required materials and conditions: Reagent lots and method versions at the time of the trial, revision histories and actual laboratory installation records
Materials to obtain first: Reagent lots and method versions at the time of the trial, revision histories and actual laboratory installation records
Further research: Map instruments, reagents, versions and installation dates to verify identity/differences between historical trials and current documents.
Remaining uncertainty: Direct information on historical/current reagent lots, versions and laboratory installations. This status reflects the documented scope of the specific narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/personal safety, the actual misdiagnosis rate, or absence of evidence worldwide.
Conditions for verification: Separate the unverified historical reagents/lots from the known identity of the 2024-10 V2.0 document.
Why this condition is needed: This is needed to avoid automatically transferring interference in historical trials to revised reagents or the versions currently installed in all laboratories.
Application exceptions: The existence of a Roche 2024 document does not verify actual installations in individual laboratories or equivalence to historical lots.
Referenced methods: C05: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed / D03: Chamgap's own diagnostic condition; formal diagnostic methodology evidence has not been reviewed / D08: Chamgap's own diagnostic applicability condition; M04 principles distinguishing reports/studies serve as general references / C09: M04 §4.5, §4.6.3; limits on the current data transformation follow the user-defined scope and are internally designed. Reason for application to the measurement family: This is needed to avoid automatically transferring interference in historical trials to revised reagents or the versions currently installed in all laboratories. This is not a formal implementation of diagnostic/QUADAS/STARD·RoB/GRADE/causality methods or clinical certification.

Related sources S01 S04 S08

N14 · Which repeated-measures contrast does Li's formal estimate represent?

Current findings: Li's formal estimate is day 7 − mean(day 0, day 14). It is a repeated-measures contrast within the same participants, not a simple change from baseline or an effect between two randomized groups. The reported 95% CI is the interval from the original model.
Verification status: Met
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: The formal contrast definition and attribution of the CI were verified. No new estimation or variance calculation was performed.
Reason for missing information: The original model's detailed specifications and checks of adjustment/multiplicity remain separate outstanding items.
Required materials and conditions: Formal repeated-measures contrast formula and model, and original estimates/CI/P for each platform
Materials to obtain first: Formal repeated-measures contrast formula and model, and original estimates/CI/P for each platform
Further research: Cross-check the original contrast formula and time-point means to distinguish formal model results from historical simple arithmetic values.
Remaining uncertainty: The original model's detailed specifications and checks of adjustment/multiplicity remain separate outstanding items. This status reflects the documented scope of the specific narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/personal safety, the actual misdiagnosis rate, or absence of evidence worldwide.
Conditions for verification: Link the within-person repeated-measures contrast day 7 − mean(day 0, day 14) to the estimates for each platform.
Why this condition is needed: This is needed to avoid confusing the simple difference obtained by subtracting the day 7 mean from the baseline mean with the formal contrast in the original model.
Application exceptions: The formal 95% CI is not converted to SD or SE, and no model is newly fitted without the original data.
Referenced methods: C06: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed / E04: M08 §8.2.2, M15 §15.3.1; internal application / E05: M15 §15.3.1–15.3.3; internal application. Reason for application to the measurement family: This is needed to avoid confusing the simple difference obtained by subtracting the day 7 mean from the baseline mean with the formal contrast in the original model. This is not a formal implementation of diagnostic/QUADAS/STARD·RoB/GRADE/causality methods or clinical certification.

Related sources S01

N15 · Were Li Roche's formal bias and historical simple difference distinguished?

Current findings: Li Roche cobas e602 TSH was 1.80→1.21→2.06 mIU/L, with a formal contrast of −0.72 mIU/L, 95% CI −1.13~−0.32, P = 0.006. −0.59 mIU/L is the historical simple before/after difference between the displayed means; it was not newly calculated.
Verification status: Met
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: The retained original Roche values and the distinction between the two contrasts were verified. They were not extended to current reagents or patient treatment effects.
Reason for missing information: Detailed verification of historical lots, actual laboratory installations and the original model.
Required materials and conditions: Li Roche TSH time-point means, formal contrast, original CI/P and display of historical arithmetic
Materials to obtain first: Li Roche TSH time-point means, formal contrast, original CI/P and display of historical arithmetic
Further research: Map platform/time-point means and the formal contrast definition to the original table to verify the roles of the different values.
Remaining uncertainty: Detailed verification of historical lots, actual laboratory installations and the original model. This status concerns the scope of documentation for that narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/individual safety, actual misdiagnosis rates or worldwide absence of evidence.
Conditions for verification: Link 1.80→1.21→2.06 and the formal −0.72/CI/P only to Roche cobas e602 and the corresponding time points.
Why this condition is needed: This is needed to avoid treating values from different contrast definitions as an error requiring correction or as the same estimate.
Application exceptions: −0.59 is the historical simple difference in the manuscript, not a new calculation in this review. It is not combined with the formal CI.
Referenced methods: C06: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed / C07: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed / E04: M08 §8.2.2, M15 §15.3.1; internal application / E05: M15 §15.3.1–15.3.3; internal application / C08: M04 §4.6.3, M15 §15.3.1–15.3.3; status separation is internally designed. Reason for application to the measurement family: This is needed to avoid treating values from different contrast definitions as an error requiring correction or as the same estimate. This is not a formal implementation of diagnostic/QUADAS/STARD·RoB/GRADE/causality methods or clinical certification.

Related sources S01

N16 · What is the scope of Li's VITROS values and observations relative to the lower reference limit?

Current findings: Ortho VITROS 5600 had means of 1.64→0.10→1.89 mIU/L, a formal contrast of −1.67 mIU/L, 95% CI −2.08~−1.26, P < 0.001. After exposure, all 6 participants were below 0.15 mIU/L, and the assay's lower reference limit was 0.47 mIU/L.
Verification status: Met
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: The retained platform values and lower limit were linked accurately. They were not converted into actual hyperthyroidism or a misdiagnosis rate.
Reason for missing information: Original individual values, reagent versions and separate patient-outcome data.
Required materials and conditions: VITROS time-point means, formal contrast/CI/P and the method's lower reference limit
Materials to obtain first: VITROS time-point means, formal contrast/CI/P and the method's lower reference limit
Further research: Distinguish the original formal contrast from individual reference-limit crossings and attribute them to the platform's measurement results.
Remaining uncertainty: Original individual values, reagent versions and separate patient-outcome data. This status concerns the scope of documentation for that narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/individual safety, actual misdiagnosis rates or worldwide absence of evidence.
Conditions for verification: Preserve the means, formal contrast, CI/P and original lower reference limit for Ortho VITROS 5600.
Why this condition is needed: This is needed to avoid turning platform-specific bias magnitudes and lower-limit crossings into findings for other assays or clinical disease incidence.
Application exceptions: The fact that all 6 participants were below the lower limit is an observation in a small measurement sample, not a population frequency.
Referenced methods: C06: M03 §3.2.4, M15 §15.3.1–15.3.3; outcome adaptations for each question are internally designed / E04: M08 §8.2.2, M15 §15.3.1; internal application / E05: M15 §15.3.1–15.3.3; internal application / D03: Chamgap's internally designed diagnostic condition; formal diagnostic-method evidence not reviewed. Reason for application to the measurement family: This is needed to avoid turning platform-specific bias magnitudes and lower-limit crossings into findings for other assays or clinical disease incidence. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality assessments, or clinical certification.

Related sources S01 S02

N17 · Was crossing the lower reference limit expressed as sensitivity, specificity or an actual misdiagnosis rate?

Current findings: The VITROS observation that all 6 participants were below the lower limit after exposure is a measurement under these conditions. It was not converted into a population misdiagnosis rate, incidence of actual hyperthyroidism or diagnostic sensitivity/specificity.
Verification status: Met
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: This condition preserves the source's stated boundary for extending measurements to clinical outcomes. It does not mean there is no patient harm.
Reason for missing information: Denominators and follow-up records for actual patient clinical assessments, actions and harms are separately needed.
Required materials and conditions: The method's reference limit, individual measurements and actual clinical assessments/follow-up outcome data
Materials to obtain first: The method's reference limit, individual measurements and actual clinical assessments/follow-up outcome data
Further research: Compare assay reference-limit crossings, independent clinical status and post-test actions separately; do not estimate patient rates without that connection.
Remaining uncertainty: Denominators and follow-up records for actual patient clinical assessments, actions and harms are separately needed. This status concerns the scope of documentation for that narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/individual safety, actual misdiagnosis rates or worldwide absence of evidence.
Conditions for verification: Separate lower-limit crossings under the test conditions from clinical disease, misdiagnosis and harm rates, and diagnostic accuracy.
Why this condition is needed: This is needed to distinguish an observation of assay values crossing the lower limit from the frequency of diagnoses/harms in patients.
Application exceptions: A measurement-bias question does not unconditionally require disease TP/FP/FN/TN tables or clinical outcome trials.
Referenced methods: D03: Chamgap's internally designed diagnostic condition; formal diagnostic-method evidence not reviewed / D07: Chamgap's internally designed diagnostic-outcome condition; formal diagnostic-method evidence not reviewed / D09: Chamgap's internally designed boundary for diagnostic extensions; formal diagnostic-method evidence not reviewed / H04: M19 §19.1.2–19.2.4; internal application / H09: Chamgap's internally designed interpretation boundary. References M19 principles; not implementation of a formal causality tool. Reason for application to the measurement family: This is needed to distinguish an observation of assay values crossing the lower limit from the frequency of diagnoses/harms in patients. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality assessments, or clinical certification.

Related sources S01 S02 S09

N18 · Was the nonsignificant result for biotin-dependent Vista also preserved?

Current findings: In the same Li specimens, Siemens Dimension Vista 1500 had −0.11 mIU/L, 95% CI −0.49~0.26, P = 0.56. Vista TSH is biotin-dependent, but there was no significant difference at this exposure. This was not interpreted as bias of 0 or equivalence.
Verification status: Met
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: The difference between the original negative finding/interval and the principle was preserved as recorded.
Reason for missing information: This observation does not establish results at other doses, blood-draw times or reagent versions.
Required materials and conditions: Vista's original assay principle, paired estimate, CI/P and the exposure conditions
Materials to obtain first: Vista's original assay principle, paired estimate, CI/P and the exposure conditions
Further research: Relate the negative observation and the range of bias still compatible with it to the original interval/exposure conditions, distinguishing them from other platforms.
Remaining uncertainty: This observation does not establish results at other doses, blood-draw times or reagent versions. This status concerns the scope of documentation for that narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/individual safety, actual misdiagnosis rates or worldwide absence of evidence.
Conditions for verification: Preserve the Vista formal contrast and CI/P from the same Li specimens together with its biotin-dependent principle.
Why this condition is needed: This is needed to avoid deleting a negative result that appears inconsistent with the principle or converting it into an effect of 0.
Application exceptions: P = 0.56 does not verify equivalence or absence of bias.
Referenced methods: C08: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is internally designed / E05: M15 §15.3.1–15.3.3; internal application / D03: Chamgap's internally designed diagnostic condition; formal diagnostic-method evidence not reviewed. Reason for application to the measurement family: This is needed to avoid deleting a negative result that appears inconsistent with the principle or converting it into an effect of 0. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality assessments, or clinical certification.

Related sources S01 S02

N19 · Was Li's nonsignificant Abbott estimate kept within the scope of the comparator method?

Current findings: Li's Abbott ARCHITECT 2000 formal contrast was −0.06 mIU/L, 95% CI −0.44~0.31, P = 0.74. Nonsignificance was not converted into absence of bias, equivalence or absence of interference at other exposures.
Verification status: Met
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: The retained Abbott values from the same specimens were linked to the comparator method's limitations.
Reason for missing information: Other versions/exposures and independent standards/traceability for the assays.
Required materials and conditions: Abbott's original comparator method, exposure conditions, paired estimate and CI/P
Materials to obtain first: Abbott's original comparator method, exposure conditions, paired estimate and CI/P
Further research: Verify the original results by distinguishing platform comparisons on the same specimens from time contrasts with pre-exposure/post-washout measurements.
Remaining uncertainty: Other versions/exposures and independent standards/traceability for the assays. This status concerns the scope of documentation for that narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/individual safety, actual misdiagnosis rates or worldwide absence of evidence.
Conditions for verification: Attribute the Abbott ARCHITECT 2000 formal contrast, interval and P to the same Li specimens.
Why this condition is needed: This is needed to avoid extending a negative observation on the comparator platform into a guarantee of no interference under all conditions.
Application exceptions: Do not count another assay on the same specimens as an additional human trial or independent participants.
Referenced methods: C08: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is internally designed / D04: Chamgap's internally designed diagnostic condition; formal diagnostic-method evidence not reviewed / E05: M15 §15.3.1–15.3.3; internal application. Reason for application to the measurement family: This is needed to avoid extending a negative observation on the comparator platform into a guarantee of no interference under all conditions. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality assessments, or clinical certification.

Related sources S01 S02

N20 · At which doses and blood-draw times was lower Roche TSH observed in Zhang?

Current findings: In the same 10 participants, Roche cobas e602 TSH was lower with 5 mg at 2 hours, P = 0.005, and with 10 mg at 2 hours and 8 hours, each P < 0.001. Exact mean differences and CIs are unverified.
Verification status: Partly verified
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: Direction, dose/time point and P are available, but direct quantitative bias and intervals remain to be verified.
Reason for missing information: Mean differences, CIs, actual analysis n by dose/blood-draw time and direct estimates between doses.
Required materials and conditions: Zhang's original Roche mean differences, variances, CIs, denominators and reported P by time point/dose
Materials to obtain first: Zhang's original Roche mean differences, variances, CIs, denominators and reported P by time point/dose
Further research: Attribute results versus baseline at each dose to their time point/assay, and check whether separate direct estimates exist for comparisons between doses.
Remaining uncertainty: Mean differences, CIs, actual analysis n by dose/blood-draw time and direct estimates between doses. This status concerns the scope of documentation for that narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/individual safety, actual misdiagnosis rates or worldwide absence of evidence.
Conditions for verification: Preserve the reported P and decreases by dose/time point in the same 10 participants, leaving unverified estimates unverified.
Why this condition is needed: This is needed to avoid turning the direction associated with a P value into a quantitative bias magnitude or a direct effect between doses.
Application exceptions: Exact mean differences and CIs are unverified. Do not extract new values from graphs or search summaries.
Referenced methods: C06: M03 §3.2.4, M15 §15.3.1–15.3.3; outcome adaptations for each question are internally designed / E05: M15 §15.3.1–15.3.3; internal application / E08: M03 §3.2.1–3.2.4; dose, duration and effect-modification details are internally designed / H02: design-specific harm questions in M19 §19.2; temporal-relationship details are internally designed. Reason for application to the measurement family: This is needed to avoid turning the direction associated with a P value into a quantitative bias magnitude or a direct effect between doses. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality assessments, or clinical certification.

Related sources S04

N21 · Were Zhang's negative TSH observations on Beckman and Abbott preserved by analyte?

Current findings: No interference was observed under the tested conditions for Zhang's Beckman UniCel DxI 800 TSH and Abbott ARCHITECT 2000 TSH. These TSH methods did not use biotin-streptavidin, and interference affecting other thyroid analytes on Beckman was not transferred to TSH.
Verification status: Partly verified
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: Direction/principle is available for these TSH methods, but exact mean differences, CIs and historical reagent details are unverified.
Reason for missing information: Quantitative results, CIs and reagent lots/versions for each TSH method.
Required materials and conditions: Each TSH method's reagents/principle, original results by dose/time and separate tables for other analytes
Materials to obtain first: Each TSH method's reagents/principle, original results by dose/time and separate tables for other analytes
Further research: Hold both instrument and analyte fixed and separately compare negative TSH observations with interference results for other analytes.
Remaining uncertainty: Quantitative results, CIs and reagent lots/versions for each TSH method. This status concerns the scope of documentation for that narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/individual safety, actual misdiagnosis rates or worldwide absence of evidence.
Conditions for verification: Distinguish the negative observations and principles for Beckman UniCel DxI 800 and Abbott ARCHITECT 2000 TSH.
Why this condition is needed: This is needed to avoid transferring interference in other thyroid analytes on the same instrument to TSH results.
Application exceptions: Nonuse of biotin-streptavidin is retained information about those TSH methods, not a guarantee for all instruments/versions.
Referenced methods: C08: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is internally designed / C06: M03 §3.2.4, M15 §15.3.1–15.3.3; outcome adaptations for each question are internally designed / D03: Chamgap's internally designed diagnostic condition; formal diagnostic-method evidence not reviewed / D08: Chamgap's internally designed diagnostic-applicability condition; general reference to M04 principles for distinguishing reports/studies. Reason for application to the measurement family: This is needed to avoid transferring interference in other thyroid analytes on the same instrument to TSH results. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality assessments, or clinical certification.

Related sources S04

N22 · Was nonsignificance at 26 hours and 50 hours converted into a universal stopping interval?

Current findings: Zhang records that no significant difference versus baseline was reported at 26 hours and 50 hours for either dose. Exact mean differences and CIs are unverified, and this is not interpreted as a universal supplement-stopping interval.
Verification status: Partly verified
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: Results at the recorded later time points are available, but do not establish bias of 0 or a universal recovery time.
Reason for missing information: Quantitative intervals and criteria for absence of interference at each time point, and duration data by population/assay.
Required materials and conditions: Original results/intervals by blood-draw time, actual dosing/stopping times and duration information by assay/population
Materials to obtain first: Original results/intervals by blood-draw time, actual dosing/stopping times and duration information by assay/population
Further research: Distinguish observations at blood-draw times from criteria for absence of interference, and compare actual persistence/resolution with the original intervals and criteria for those conditions.
Remaining uncertainty: Quantitative intervals and criteria for absence of interference at each time point, and duration data by population/assay. This status concerns the scope of documentation for that narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/individual safety, actual misdiagnosis rates or worldwide absence of evidence.
Conditions for verification: Preserve reports of nonsignificance versus baseline at 26/50 hours for both doses only within the original conditions.
Why this condition is needed: This is needed to avoid extending nonsignificance at tested time points into the time when interference ends for all people, doses and assays.
Application exceptions: Time points after exposure stops are not recommendations for individuals to stop taking the supplement. Nonsignificance is not equivalence either.
Referenced methods: C08: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is internally designed / E08: M03 §3.2.1–3.2.4; dose, duration and effect-modification details are internally designed / H02: design-specific harm questions in M19 §19.2; temporal-relationship details are internally designed. Reason for application to the measurement family: This is needed to avoid extending nonsignificance at tested time points into the time when interference ends for all people, doses and assays. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality assessments, or clinical certification.

Related sources S04 S09

N23 · Was the direction corroborated by Ylli distinguished from unverified quantitative tables?

Current findings: Ylli reported 13 adults, 10 mg/day for 8 days, and measurements on day 1/day 8 before dosing, at 2 hours and at 5 hours. The abstract supports Roche changes and the greatest interference at 2 hours, but full-text quantitative bias is unverified, and percentages from searches were not imported.
Verification status: Partly verified
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: The abstract's direction and timeline are available, but quantitative tables, exact analysis denominators/CIs remain to be verified.
Reason for missing information: Quantitative bias, analysis n and CIs from the original full-text tables.
Required materials and conditions: Ylli's original full-text quantitative tables, TSH analysis n/differences/CIs by time point and the abstract's role
Materials to obtain first: Ylli's original full-text quantitative tables, TSH analysis n/differences/CIs by time point and the abstract's role
Further research: Match the abstract/figure captions to the original tables to distinguish the level of directional verification from numerical verification.
Remaining uncertainty: Quantitative bias, analysis n and CIs from the original full-text tables. This status concerns the scope of documentation for that narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/individual safety, actual misdiagnosis rates or worldwide absence of evidence.
Conditions for verification: Record 10 mg/day, 8 days, day 1/day 8, predose/2/5 hours and the Roche direction within the scope of the abstract.
Why this condition is needed: This is needed to avoid filling in the direction in the abstract/figure captions with percentages/bias magnitudes from full-text tables.
Application exceptions: Do not import percentages from search summaries. The existence of a PMCID does not mean the full text was read.
Referenced methods: C03: data collection/selection principles in M04 §4.5–4.6; separation of access from reading and the hyperlink contract are internally designed / C06: M03 §3.2.4, M15 §15.3.1–15.3.3; outcome adaptations for each question are internally designed / E05: M15 §15.3.1–15.3.3; internal application / D08: Chamgap's internally designed diagnostic-applicability condition; general reference to M04 principles for distinguishing reports/studies. Reason for application to the measurement family: This is needed to avoid filling in the direction in the abstract/figure captions with percentages/bias magnitudes from full-text tables. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality assessments, or clinical certification.

Related sources S05

N24 · What are the exact version, product and platforms of the Roche method document?

Current findings: The retained document is Roche Elecsys TSH US 2024-10 V2.0, document 08429324501V2.0, product ref 08429324160. It describes that reagent's performance on cobas e411/e601/e602 and does not verify current laboratory installations.
Verification status: Met
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: The retained document's identity and scope of applicability were linked. Historical/current reagent equivalence or installation was not certified.
Reason for missing information: Historical lots and current laboratory installation/revision histories.
Required materials and conditions: Roche method document version, document/product identifiers, supported platforms and installation/revision data
Materials to obtain first: Roche method document version, document/product identifiers, supported platforms and installation/revision data
Further research: Link document identifiers to applicable platforms, and separately compare whether the versions at the time of testing/currently installed match.
Remaining uncertainty: Historical lots and current laboratory installation/revision histories. This status concerns the scope of documentation for that narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/individual safety, actual misdiagnosis rates or worldwide absence of evidence.
Conditions for verification: Preserve 2024-10 V2.0, 08429324501V2.0, 08429324160 and the e411/e601/e602 scope exactly as recorded.
Why this condition is needed: This is needed to avoid using a specific version of the method document as evidence of identical performance for all historical Roche reagents.
Application exceptions: The currently retained document version and the versions actually installed in all laboratories are different facts.
Referenced methods: C05: M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed / D03: Chamgap's internally designed diagnostic condition; formal diagnostic-method evidence not reviewed / D08: Chamgap's internally designed diagnostic-applicability condition; general reference to M04 principles for distinguishing reports/studies. Reason for application to the measurement family: This is needed to avoid using a specific version of the method document as evidence of identical performance for all historical Roche reagents. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality assessments, or clinical certification.

Related sources S08

N25 · What do the document's biotin test range and allowable deviations mean?

Current findings: The Roche document specifies a test range of biotin ≤1200 ng/mL. At TSH ≤0.2 µIU/mL, the allowable deviation is ≤0.02 µIU/mL; above that, it is ≤10%. This is an analytical performance document, not an oral safe dose or a guarantee of no interference in all laboratories.
Verification status: Met
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: The original analytical acceptance values were accurately linked to their nonclinical scope.
Reason for missing information: Direct comparison of actual laboratory installations/exposure conditions with human applicability.
Required materials and conditions: The method document's test concentrations, allowable deviations, validation conditions and revision/installation information
Materials to obtain first: The method document's test concentrations, allowable deviations, validation conditions and revision/installation information
Further research: Compare the document's concentrations, TSH ranges and allowable deviations, and keep human oral-exposure/clinical-safety questions separate.
Remaining uncertainty: Direct comparison of actual laboratory installations/exposure conditions with human applicability. This status concerns the scope of documentation for that narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/individual safety, actual misdiagnosis rates or worldwide absence of evidence.
Conditions for verification: Record ≤1200 ng/mL, an allowable deviation at TSH ≤0.2 µIU/mL of ≤0.02 µIU/mL, and ≤10% at higher TSH within the document's scope.
Why this condition is needed: This is needed to avoid turning an analytical validation concentration into an oral safe dose or a guarantee of bias of 0.
Application exceptions: Do not make new conversions between document concentrations and intake amounts. Allowable deviations differ from the absolute absence of interference.
Referenced methods: C06: M03 §3.2.4, M15 §15.3.1–15.3.3; outcome adaptations for each question are internally designed / D03: Chamgap's internally designed diagnostic condition; formal diagnostic-method evidence not reviewed / E05: M15 §15.3.1–15.3.3; internal application / H09: Chamgap's internally designed interpretation boundary. References M19 principles; not implementation of a formal causality tool. Reason for application to the measurement family: This is needed to avoid turning an analytical validation concentration into an oral safe dose or a guarantee of bias of 0. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality assessments, or clinical certification.

Related sources S08

N26 · Was Li's published unit correction applied to the original units?

Current findings: Under the 2017-11-21 correction, Li's serum-biotin unit was retained as pg/mL. TSH in mIU/L was unchanged. The S03 correction belongs to the same Li report family and is not an independent human trial.
Verification status: Met
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: This is a documentation condition linking the retained unit correction to its applicability.
Reason for missing information: No new search was conducted in this review for additional corrections/retractions after the reference date.
Required materials and conditions: Identity and original wording of the published correction, units before/after correction and locations where it applies
Materials to obtain first: Identity and original wording of the published correction, units before/after correction and locations where it applies
Further research: Compare the correction with its linked numbers/units, and do not change values/units outside its applicability.
Remaining uncertainty: No new search was conducted in this review for additional corrections/retractions after the reference date. This status concerns the scope of documentation for that narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/individual safety, actual misdiagnosis rates or worldwide absence of evidence.
Conditions for verification: Under the 2017-11-21 correction, distinguish biotin in pg/mL from TSH in mIU/L, which was unchanged.
Why this condition is needed: This is needed to avoid repeating the serum-biotin unit error in citations or also changing TSH units.
Application exceptions: Preserve the correction's original bibliographic information, including PMID/DOI. This is not a new external correction check or numerical conversion in this review.
Referenced methods: C08: M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is internally designed / C09: M04 §4.5, §4.6.3; limitations on the current data transformation follow the user's scope and internal design / C06: M03 §3.2.4, M15 §15.3.1–15.3.3; outcome adaptations for each question are internally designed. Reason for application to the measurement family: This is needed to avoid repeating the serum-biotin unit error in citations or also changing TSH units. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality assessments, or clinical certification.

Related sources S01 S03

N27 · Is day 7 biotin of 3601 an actual precisely measured concentration?

Current findings: The day 7 value of 3601 was assigned for analysis because all measurements exceeded 3600. It was not interpreted as an exact measured serum-biotin concentration or an individual dose-concentration relationship.
Verification status: Met
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: The meaning of the retained upper-limit exceedance and assigned analysis value was verified.
Reason for missing information: Exact concentrations above the upper limit and individual concentration-bias relationships are unverified.
Required materials and conditions: Serum-biotin measurement range, handling of values above the upper limit and the actual analytical assignment rule
Materials to obtain first: Serum-biotin measurement range, handling of values above the upper limit and the actual analytical assignment rule
Further research: Compare the original detection range and assignment handling to distinguish actual observations, values above the upper limit and model inputs.
Remaining uncertainty: Exact concentrations above the upper limit and individual concentration-bias relationships are unverified. This status concerns the scope of documentation for that narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/individual safety, actual misdiagnosis rates or worldwide absence of evidence.
Conditions for verification: Preserve the original statement that all day 7 measurements exceeded 3600 and were assigned 3601.
Why this condition is needed: This is needed to avoid using an assigned analysis value above the upper detection limit as an exact serum concentration or dose-concentration relationship.
Application exceptions: Do not convert 3601 and 3600 to other units or calculate new concentration/bias functions.
Referenced methods: C06: M03 §3.2.4, M15 §15.3.1–15.3.3; outcome adaptations for each question are internally designed / E05: M15 §15.3.1–15.3.3; internal application / C07: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed. Reason for application to the measurement family: This is needed to avoid using an assigned analysis value above the upper detection limit as an exact serum concentration or dose-concentration relationship. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality assessments, or clinical certification.

Related sources S01 S03

N28 · Are results for other thyroid analytes/nonhormone analytes applied to this TSH question?

Current findings: Interference in other thyroid analytes on Beckman was not transferred to TSH. Nonhormone assay results in the title of the Li paper and the FDA troponin safety document are also not combined as direct numerical evidence of this TSH bias.
Verification status: Not applicable
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: Direct assessment of other analytes is outside the selected TSH question. This status does not convert Not read into Not applicable.
Reason for missing information: Effects, harms and accuracy for other analytes must be reviewed with separate boundaries and direct data.
Required materials and conditions: Analyte-specific result tables within the paper/instrument and the original selected-endpoint boundary
Materials to obtain first: Analyte-specific result tables within the paper/instrument and the original selected-endpoint boundary
Further research: Separate results by analyte-platform-exposure-time point to prevent transferring other endpoints that share the same instrument name.
Remaining uncertainty: Effects, harms and accuracy for other analytes must be reviewed with separate boundaries and direct data. This status concerns the scope of documentation for that narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/individual safety, actual misdiagnosis rates or worldwide absence of evidence.
Conditions for verification: Limit the currently selected outcome to TSH and leave extensions to other analytes/treatment/patient outcomes as separate questions.
Why this condition is needed: This is needed to avoid combining interference in other analytes from the same paper or instrument into TSH bias.
Application exceptions: Do not delete other results or judge them invalid. This exception means they are outside the scope of this standalone table.
Referenced methods: C01: question-clarification principles in M03 §3.1, §3.2.1–3.2.4; detailed separation rules are internally designed / C06: M03 §3.2.4, M15 §15.3.1–15.3.3; outcome adaptations for each question are internally designed / E09: M03 §3.2.4; internally designed boundary for extensions / D09: Chamgap's internally designed boundary for diagnostic extensions; formal diagnostic-method evidence not reviewed. Reason for application to the measurement family: This is needed to avoid combining interference in other analytes from the same paper or instrument into TSH bias. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality assessments, or clinical certification.

Related sources S01 S04 S07

N29 · Can measurements/analyses and missingness be linked by platform and time point?

Current findings: Li's 6 participants and 18 time-point specimens are retained. Zhang's exact analyzed-specimen counts by platform/time point and Ylli's detailed TSH analysis denominators are unverified. The current data were not used to create claims of no missingness/exclusions or a common analysis n.
Verification status: Unverified
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: Original data are insufficient to fully link the analysis flow for each platform/time point.
Reason for missing information: Original flow of successful measurements, analyses and reasons for missingness/exclusion by time point/platform.
Required materials and conditions: Participant→blood draw→specimen→platform measurement→analysis flow and handling of indeterminate/excluded/missing results
Materials to obtain first: Participant→blood draw→specimen→platform measurement→analysis flow and handling of indeterminate/excluded/missing results
Further research: Compare the actual measurement/analysis flow by platform and time point, and do not arbitrarily fill missing results with normal/0.
Remaining uncertainty: Original flow of successful measurements, analyses and reasons for missingness/exclusion by time point/platform. This status concerns the scope of documentation for that narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/individual safety, actual misdiagnosis rates or worldwide absence of evidence.
Conditions for verification: Separate currently known participants/specimens from the unverified platform-specific analysis flow.
Why this condition is needed: This is needed to avoid substituting enrollment/participant counts or time-point specimen counts as the actual denominator for every analysis.
Application exceptions: Do not present the absence of a detailed flow as 0 missing results or no exclusions.
Referenced methods: C07: M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed / D06: Chamgap's internally designed diagnostic condition; formal diagnostic-method evidence not reviewed / H06: M19 §19.1.2–19.2.4, M04 §4.6.3; internal application. Reason for application to the measurement family: This is needed to avoid substituting enrollment/participant counts or time-point specimen counts as the actual denominator for every analysis. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality assessments, or clinical certification.

Related sources S01 S04 S05

N30 · To what level were measurement procedures, calibration/QC and specimen handling verified?

Current findings: Retained S01/S02/S04 contain historical locations where methods/assay principles were verified. The KO/structure currently read does not embed detailed values for calibration/QC, storage or measurement order/reading, so those procedures were not established.
Verification status: Unverified
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: The existence of a verification location differs from the detailed values embedded in the retained summary read in this review.
Reason for missing information: Actual comparison of original methodological procedures, calibration/QC, specimen handling and measurement/reading records.
Required materials and conditions: Assay-specific calibration/QC, specimen collection/storage, measurement order, reading/blinding and original methodological procedures
Materials to obtain first: Assay-specific calibration/QC, specimen collection/storage, measurement order, reading/blinding and original methodological procedures
Further research: Compare handling/calibration/measurement conditions for the same specimens to verify procedures that could explain differences between time points/platforms.
Remaining uncertainty: Actual comparison of original methodological procedures, calibration/QC, specimen handling and measurement/reading records. This status concerns the scope of documentation for that narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/individual safety, actual misdiagnosis rates or worldwide absence of evidence.
Conditions for verification: Distinguish the original verification locations from the information currently embedded, leaving gaps in comparison of calibration/QC, storage and measurement order/reading.
Why this condition is needed: This is needed to avoid claiming that all analytical procedures and alternative explanations were verified solely from platform names and full-text reading labels.
Application exceptions: This is limited to the absence of detailed procedural values in the KO/structure currently read. It does not mean that the entire original full text failed to report procedures.
Referenced methods: D03: Chamgap's internally designed diagnostic condition; formal diagnostic-method evidence not reviewed / D05: Chamgap's internally designed diagnostic condition; formal diagnostic-method evidence not reviewed / E03: M08 Table 8.2.a, M03 §3.2.4; internal application. Reason for application to the measurement family: This is needed to avoid claiming that all analytical procedures and alternative explanations were verified solely from platform names and full-text reading labels. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality assessments, or clinical certification.

Related sources S01 S02 S04

N31 · Were registration, protocol and SAP compared with actual platforms/time points/contrasts?

Current findings: Li's NCT03034707 and Zhang's ChiCTR1800020472 identifiers are retained. Some registration histories, protocols and SAPs, as well as numerical supplements/full tables that were not accessible in the historical record, are currently unverified. Agreement with the original plan or selective reporting was not established.
Verification status: Unverified
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: Identifiers and analysis locations alone do not complete the comparison with advance plans/multiplicity.
Reason for missing information: Actual original-source comparison of registration histories, plan versions and the complete reports/supplements.
Required materials and conditions: NCT03034707 and ChiCTR1800020472 histories, protocol/SAP, plans for platforms/endpoints/time points and numerical supplements
Materials to obtain first: NCT03034707 and ChiCTR1800020472 histories, protocol/SAP, plans for platforms/endpoints/time points and numerical supplements
Further research: Compare registration/plan versions and dates with the contrasts/time points actually reported, distinguishing reasons for changes and handling of multiplicity.
Remaining uncertainty: Actual original-source comparison of registration histories, plan versions and the complete reports/supplements. This status concerns the scope of documentation for that narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/individual safety, actual misdiagnosis rates or worldwide absence of evidence.
Conditions for verification: Link registration identifiers to original analysis locations and record that plans/multiplicity and the full numerical supplements have not been compared.
Why this condition is needed: This is needed to avoid arbitrarily establishing that favorable reported platforms/time points match the original advance plan.
Application exceptions: Do not convert unverified registration/planning into confirmed nonregistration or selective reporting.
Referenced methods: E04: M08 §8.2.2, M15 §15.3.1; internal application / E06: M08 Table 8.2.a, M04 §4.6.3; internal application / C09: M04 §4.5, §4.6.3; limitations on the current data transformation follow the user's scope and internal design / D05: Chamgap's internally designed diagnostic condition; formal diagnostic-method evidence not reviewed. Reason for application to the measurement family: This is needed to avoid arbitrarily establishing that favorable reported platforms/time points match the original advance plan. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality assessments, or clinical certification.

Related sources S01 S02 S04 S05

N32 · Were reports, platforms, corrections and method documents counted as independent human replications?

Current findings: F01's Li main article S01, supplement S02 and correction S03 belong to the same family. F02's Zhang S04, F03's Ylli S05 and A01's manufacturer document S08 have distinct roles. Multiple platforms, 12 bibliographic entries and secondary citations in official documents were not counted as 12 human replications.
Verification status: Met
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: The retained family identities and report roles have been linked. Replication was not calculated from the number of platforms or bibliographic entries.
Reason for missing information: Do not assume that evidence levels or population/reagent conditions are the same, or add up unverified unique participants.
Required materials and conditions: Report-family-assay/outcome relationships and links to registrations, corrections, method documents and repeat citations
Materials to obtain first: Report-family-assay/outcome relationships and links to registrations, corrections, method documents and repeat citations
Further research: Map unique participant families to report, platform and document types, and assess independence and evidence level separately.
Remaining uncertainty: Do not assume that evidence levels or population/reagent conditions are the same, or add up unverified unique participants. This status describes the scope of the record for the specified narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/individual safety, the actual misdiagnosis rate, or a worldwide absence of data.
Conditions for verification: Link the identities and roles of F01's S01/S02/S03, F02's S04, F03's S05 and A01's S08.
Why this condition is needed: This is needed to avoid adding together the main article/supplement/correction from the same study, multiple platforms using the same specimens, and manufacturer documents as independent human replications.
Application exceptions: The direct data from F01/F02 and the abstract-level corroboration from F03 differ in evidence level. A01 is not a human study.
Referenced methods: C02: Distinction between studies and reports in M04 §4.6.1–4.6.2; linking cohorts/outcomes is an internal application / E07: M04 §4.6.1–4.6.2, M15 §15.3.1; internal application / H07: M04 §4.6.1–4.6.2; adaptation for harm data is internally designed / D08: Chamgap's own diagnostic-application condition; general reference to M04's principle of distinguishing reports from studies. Reason for application to the measurement family: This is needed to avoid adding together the main article/supplement/correction from the same study, multiple platforms using the same specimens, and manufacturer documents as independent human replications. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality methods, or clinical certification.

Related sources S01 S02 S03 S04 S05 S08

N33 · To which report do funding, product provision and author relationships belong?

Current findings: Li records NIH, university and participating-laboratory support and author-specific commercial relationships as disclosed in the original source. Zhang declares no funding/conflicts of interest; this is not independent verification. Ylli's detailed funding and product roles are unverified, and the Roche method document is a manufacturer document.
Verification status: Partly verified
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: The verification levels of the reports are distinguished, but full comparison against the original detailed declarations and product roles remains outstanding.
Reason for missing information: Original detailed declarations of funding, product supply/roles and author relationships for each report.
Required materials and conditions: Study-specific funding, product roles, author relationships, declarations in manufacturer performance documents, and their original locations
Materials to obtain first: Study-specific funding, product roles, author relationships, declarations in manufacturer performance documents, and their original locations
Further research: Compare the funding/supply/declarations for the relevant report without transferring them to the independence of another study or the validity of its results.
Remaining uncertainty: Original detailed declarations of funding, product supply/roles and author relationships for each report. This status describes the scope of the record for the specified narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/individual safety, the actual misdiagnosis rate, or a worldwide absence of data.
Conditions for verification: Retain Li's support/relationships, Zhang's declaration of none, Ylli's unverified details and the Roche manufacturer document separately.
Why this condition is needed: This is needed to avoid treating manufacturer documents or unverified funding as independent performance validation.
Application exceptions: Support or competing interests do not automatically invalidate a result, and a declaration of none does not establish independent verification.
Referenced methods: C10: Chamgap's own independence and attribution condition. The official methods sections used in this demonstration do not warrant all of these detailed items / C02: Distinction between studies and reports in M04 §4.6.1–4.6.2; linking cohorts/outcomes is an internal application. Reason for application to the measurement family: This is needed to avoid treating manufacturer documents or unverified funding as independent performance validation. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality methods, or clinical certification.

Related sources S01 S04 S05 S08

N34 · Has current reading of local summaries been distinguished from historical external access and access dates?

Current findings: The current stored manuscript's 17 KO fields, 4 structured evidence entries and 12 bibliographic entries, plus measurement/display/correction and historical metadata, were read. Historical full text/PDF access, official extracts, abstracts and access failures are historical records. All external materials remain unread in this review; individual access dates are null, and the original review date, 2026-09-15, is separate.
Verification status: Met
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: This is a record condition that separates materials actually read in the current review from historical access and dates.
Reason for missing information: The information currently available does not establish report-specific actual access dates or preservation/SHA of historical original binaries.
Required materials and conditions: Physical material types, URLs, historical access_level/location, report-specific access-date records and actions in this review
Materials to obtain first: Physical material types, URLs, historical access_level/location, report-specific access-date records and actions in this review
Further research: Compare each link's actual material type with its historical access level, and record dates/current access events separately.
Remaining uncertainty: The information currently available does not establish report-specific actual access dates or preservation/SHA of historical original binaries. This status describes the scope of the record for the specified narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/individual safety, the actual misdiagnosis rate, or a worldwide absence of data.
Conditions for verification: Separate current reading of the retained KO/structure and bibliography from unattempted access, non-acquisition and non-reading for each external material type, and from historical access levels.
Why this condition is needed: This is needed to avoid elevating publisher_full_text or other historical access_level values, or links, to original-source reading in this review.
Application exceptions: The original verified_date is a global review date. If a report-specific access date is absent, it remains null; historical access failures are not displayed as current failures.
Referenced methods: C03: Data collection/selection principles in M04 §4.5–4.6; separation of access from reading and the hyperlink contract are internally designed / C09: M04 §4.5, §4.6.3; limits on the current data transition follow the user-defined scope and internal design. Reason for application to the measurement family: This is needed to avoid elevating publisher_full_text or other historical access_level values, or links, to original-source reading in this review. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality methods, or clinical certification.

Related sources S01 S02 S03 S04 S05 S06 S07 S08 S09 S10 S11 S12

N35 · Were discovery leads for S10/S11/S12 elevated to direct performance figures?

Current findings: S10 ETA2026 is a historical record of metadata discovery only and a failed attempt to access the publisher's full text. The original concentration-response tables for S11 LOCI and the original extraction for S12 routine immunoassays were also unverified at that time. These were not elevated to new access or direct quantitative evidence in this review.
Verification status: Unverified
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: The currently retained summaries contain no direct performance or concentration-response information.
Reason for missing information: Actual comparison against the three candidates' original full texts and tables, their currency and the reagents to which they apply.
Required materials and conditions: Original full texts/concentration-response tables and identity/access records for the S10 guideline, S11 LOCI and S12 clinical-measurement candidates
Materials to obtain first: Original full texts/concentration-response tables and identity/access records for the S10 guideline, S11 LOCI and S12 clinical-measurement candidates
Further research: Link discovered bibliographic records to full-text results without extracting or estimating concentrations/bias figures from tables that were not accessed.
Remaining uncertainty: Actual comparison against the three candidates' original full texts and tables, their currency and the reagents to which they apply. This status describes the scope of the record for the specified narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/individual safety, the actual misdiagnosis rate, or a worldwide absence of data.
Conditions for verification: Retain the actual identities of the three candidates, the scope of historical discovery/failure, and the unverified original tables.
Why this condition is needed: This is needed to avoid inventing original quantitative tables from the titles of guideline, LOCI and routine immunoassay papers whose full texts were not accessed.
Application exceptions: Separate unattempted access in the current review from historical full-text access failures. A link/PMCID is not evidence that the full text was read.
Referenced methods: C03: Data collection/selection principles in M04 §4.5–4.6; separation of access from reading and the hyperlink contract are internally designed / C09: M04 §4.5, §4.6.3; limits on the current data transition follow the user-defined scope and internal design / C08: M04 §4.6.3, M15 §15.3.1–15.3.3; status separation is internally designed. Reason for application to the measurement family: This is needed to avoid inventing original quantitative tables from the titles of guideline, LOCI and routine immunoassay papers whose full texts were not accessed. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality methods, or clinical certification.

Related sources S10 S11 S12

N36 · Were the historical NIH/FDA extracts counted as independent TSH studies?

Current findings: NIH S06 and FDA S07 inherit the original sources, extracts and access records from earlier work, with no new search. They are general safety materials and were not counted as independent TSH studies or evidence of the same bias across all analytes.
Verification status: Met
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: The distinction between official background, historical inheritance and independent replication was verified. The official documents have not been newly read in the current review.
Reason for missing information: No current comparison against the previous separate extraction/access logs and original official documents was performed.
Required materials and conditions: Historical NIH/FDA extracts, original access histories, and the documents' actual scope of analytes/secondary citations
Materials to obtain first: Historical NIH/FDA extracts, original access histories, and the documents' actual scope of analytes/secondary citations
Further research: Link safety background/secondary citations in official documents to unique studies and distinguish them from independent results.
Remaining uncertainty: No current comparison against the previous separate extraction/access logs and original official documents was performed. This status describes the scope of the record for the specified narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/individual safety, the actual misdiagnosis rate, or a worldwide absence of data.
Conditions for verification: Retain S06/S07's inherited_official_extract status, general safety role and boundary of no new search.
Why this condition is needed: This is needed to avoid double-counting official general safety documents and secondary citations as independent human measurement results.
Application exceptions: Do not transfer the analyte scope of the FDA troponin document to direct TSH figures.
Referenced methods: C02: Distinction between studies and reports in M04 §4.6.1–4.6.2; linking cohorts/outcomes is an internal application / C03: Data collection/selection principles in M04 §4.5–4.6; separation of access from reading and the hyperlink contract are internally designed / H09: Chamgap's own interpretation boundary. Reference to M19 principles, not implementation of a formal causality tool. Reason for application to the measurement family: This is needed to avoid double-counting official general safety documents and secondary citations as independent human measurement results. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality methods, or clinical certification.

Related sources S06 S07

N37 · Is AACC guidance distinguished from individual stopping intervals and testing/treatment schedules?

Current findings: S09 AACC2020 guidance is a historical original-source record of mechanisms, assay specificity, renal elimination and recommendations. The original table does not prescribe an individual's supplement stopping interval, testing schedule or treatment change, and prohibits a universal stopping interval.
Verification status: Partly verified
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: The role of the guidance and scope of action have been linked, but the original recommendation context that is not currently embedded, and individual conditions, have not been verified.
Reason for missing information: The original recommendation context for the relevant conditions and information specific to actual exposure/installations and populations.
Required materials and conditions: The actual context of guidance recommendations by population, renal function/exposure and assay, and individual testing conditions
Materials to obtain first: The actual context of guidance recommendations by population, renal function/exposure and assay, and individual testing conditions
Further research: Compare assay/population-specific guidance conditions with actual installations and exposure, without generalizing to a universal interval or individual action.
Remaining uncertainty: The original recommendation context for the relevant conditions and information specific to actual exposure/installations and populations. This status describes the scope of the record for the specified narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/individual safety, the actual misdiagnosis rate, or a worldwide absence of data.
Conditions for verification: Link AACC's historical scope to the prohibition on a universal stopping interval or individual treatment changes.
Why this condition is needed: This is needed to avoid converting general guidance or study time points into a safe stopping interval for a particular person.
Application exceptions: The original numerical recommendations in the guidance are not embedded in the current JSON, so no new values are presented.
Referenced methods: D09: Chamgap's own boundary for diagnostic extensions; official diagnostic-method evidence not reviewed / E08: M03 §3.2.1–3.2.4; dose, duration and effect-modification details are internally designed / H02: Design-specific harm questions in M19 §19.2; timing-relationship details are internally designed / H08: M19 §19.1.2–19.2.4; internal application. Reason for application to the measurement family: This is needed to avoid converting general guidance or study time points into a safe stopping interval for a particular person. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality methods, or clinical certification.

Related sources S09

N38 · What possibility and what actual observations does the Warning represent?

Current findings: The original safety status is Warning. This reflects the possibility that falsely low TSH could lead to interpretation errors; the direct observations are assay-specific bias and reference-limit crossing. The incidence of actual patient harm is not an established result.
Verification status: Partly verified
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: The original reason for the Warning and the level of direct observation have been retained. There are no data establishing the frequency/causation of actual harm.
Reason for missing information: Actual definitions and collection of patient events, denominators/follow-up, post-test actions and alternative causes.
Required materials and conditions: Reference-limit crossing of measured values, actual clinical judgments/actions after testing, and harm definitions/collection/denominators/follow-up
Materials to obtain first: Reference-limit crossing of measured values, actual clinical judgments/actions after testing, and harm definitions/collection/denominators/follow-up
Further research: Compare analytical bias separately with the timing, alternative explanations and denominators for post-test decisions and patient events to verify the scope of direct harm evidence.
Remaining uncertainty: Actual definitions and collection of patient events, denominators/follow-up, post-test actions and alternative causes. This status describes the scope of the record for the specified narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/individual safety, the actual misdiagnosis rate, or a worldwide absence of data.
Conditions for verification: Retain the original safety Warning, measured values and reference-limit crossing, while distinguishing the absence of data on actual misdiagnosis/harm.
Why this condition is needed: This is needed to avoid converting the possibility of interpretation errors from falsely low measurements into an actual patient harm rate or established causation of an event.
Application exceptions: Do not reuse the presence of measurement bias as a judgment of individual safety/efficacy.
Referenced methods: H01: M19 §19.1.2–19.2.4; detailed distinctions are internally designed / H04: M19 §19.1.2–19.2.4; internal application / H09: Chamgap's own interpretation boundary. Reference to M19 principles, not implementation of a formal causality tool / D09: Chamgap's own boundary for diagnostic extensions; official diagnostic-method evidence not reviewed. Reason for application to the measurement family: This is needed to avoid converting the possibility of interpretation errors from falsely low measurements into an actual patient harm rate or established causation of an event. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality methods, or clinical certification.

Related sources S01 S04 S09

N39 · Have bias magnitude and duration outside the healthy-adult conditions been verified?

Current findings: These healthy-adult data did not establish bias magnitude or duration in populations with renal impairment, pregnancy, childhood or high-dose treatment. Do not generalize to individual stopping intervals or long-term safety.
Verification status: Unverified
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: The currently retained materials contain no direct measurement information beyond the selected healthy-adult conditions.
Reason for missing information: Direct data on quantitative bias, intervals and duration by population, exposure and reagent.
Required materials and conditions: Actual exposure, reagents and blood-draw-time-specific bias/duration information for populations defined by renal function, pregnancy, childhood or high-dose treatment
Materials to obtain first: Actual exposure, reagents and blood-draw-time-specific bias/duration information for populations defined by renal function, pregnancy, childhood or high-dose treatment
Further research: Compare exposure/elimination, underlying conditions and assay/time-point data for special populations, and distinguish them from healthy-adult results.
Remaining uncertainty: Direct data on quantitative bias, intervals and duration by population, exposure and reagent. This status describes the scope of the record for the specified narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/individual safety, the actual misdiagnosis rate, or a worldwide absence of data.
Conditions for verification: Record the direct study conditions separately from unverified information on special populations and long-term/rare situations.
Why this condition is needed: This is needed to avoid extending the results of short-term exposure in healthy adults to all populations with renal impairment, pregnancy, childhood or high-dose treatment.
Application exceptions: Studies in every vulnerable population are not mandatory to establish this narrow measurement question, but direct information is required for the corresponding extension claims.
Referenced methods: C04: M03 §3.2.1; detailed population conditions are internally designed / H08: M19 §19.1.2–19.2.4; internal application / E08: M03 §3.2.1–3.2.4; dose, duration and effect-modification details are internally designed. Reason for application to the measurement family: This is needed to avoid extending the results of short-term exposure in healthy adults to all populations with renal impairment, pregnancy, childhood or high-dose treatment. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality methods, or clinical certification.

Related sources S01 S04 S05 S09

N40 · Which retained reference date underlies the statements, and what changes trigger a new review?

Current findings: The evidence-review date is 2026-09-15, and this retained-material transition is dated 2026-10-05. The original revision_history records the initial measurement-only current value and retains the unit correction. No new search, original-source verification or verification of reagent installations/the latest guidance was performed.
Verification status: Partly verified
Materials actually read: Summary read: The specified pointers and original values in the current stored manuscript were actually read. Access to these external material types was not attempted in this review; they were neither acquired nor read.
Why unverified: The recorded reference date and reasons for updates have been linked, but up-to-date completeness and actual current installations have not been verified.
Reason for missing information: Authorized actual comparison of reagent/publication changes, corrections, retractions and numerical/classification changes after the reference date.
Required materials and conditions: Reference date, current review date, search/access records, reagent revisions, original corrections/retractions, and new numerical/classification data
Materials to obtain first: Reference date, current review date, search/access records, reagent revisions, original corrections/retractions, and new numerical/classification data
Further research: Retain before/after original values, versions, dates and access levels under the same ID, and compare the basis for changes and revisions of conditions as separate events.
Remaining uncertainty: Authorized actual comparison of reagent/publication changes, corrections, retractions and numerical/classification changes after the reference date. This status describes the scope of the record for the specified narrow measurement condition. It does not establish absence of interference, equivalence, efficacy/individual safety, the actual misdiagnosis rate, or a worldwide absence of data.
Conditions for verification: Link the evidence-review date of 2026-09-15 and this review date to unverified information, corrections/revisions and the update scope.
Why this condition is needed: This is needed to avoid overstating the retained current value as verification of all the latest literature or current installations, or as an exhaustive search.
Application exceptions: Verification of new reagent documents, corrections, retractions and numerical/classification errors is not a request for automatic execution now.
Referenced methods: C09: M04 §4.5, §4.6.3; limits on the current data transition follow the user-defined scope and internal design / C08: M04 §4.6.3, M15 §15.3.1–15.3.3; status separation is internally designed / C03: Data collection/selection principles in M04 §4.5–4.6; separation of access from reading and the hyperlink contract are internally designed. Reason for application to the measurement family: This is needed to avoid overstating the retained current value as verification of all the latest literature or current installations, or as an exhaustive search. This is not formal implementation of diagnostic/QUADAS/STARD, RoB/GRADE or causality methods, or clinical certification.

Related sources S03 S08 S10